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Bacteria need suitable and resourceful environments to live and reproduce,
including soil, oceans, plants, animals and humans. Streptococci are Gram positive
pathogens that have the ability to infect a wide variety of hosts including fish, horses,
swine, cattle and humans. Among the many streptococcus species, Streptococcus
agalactiae (Group B streptococcus or GBS) is an opportunistic pathogen that has been
identified as the leading cause of sepsis and meningitis in neonates, in addition to
causing invasive and systemic infections in immunocompromised individuals. To survive
inside different host environments, bacteria utilize many virulence factors to combat the
host immune response, including the bacterial cell wall and capsule. In Gram positive
pathogens, the LytR-CpsA-Psr (LCP) family of proteins are vital to the proper synthesis
and assembly of both the cell wall and capsule. Three main members of the LCP family
proteins have been identified in GBS, including the CpsA, the Psr, and the LytR (BrpA)
proteins.
This dissertation aimed to examine the effect of the GBS LCP proteins, CpsA
and Psr, on vitality of GBS. We showed that both the Psr protein and the CpsA protein
play an important role in cell wall integrity, antibiotic sensitivity, and virulence of GBS.

The double deletion of genes encoding CpsA and Psr resulted in an exacerbated effect
on these processes, alluding to the idea that the two proteins are partially compensatory
in function.
In addition, work reported in this dissertation aimed to examine the roles of
different domains within the CpsA protein in GBS, including the extracellular accessory
domain and the highly mobile interdomain region between the accessory and the LytR
domains. Results demonstrated that while the absence of the accessory domain and
the interdomain region cause the formation of longer cocci chains, it appears to have no
significant effect on capsule production in GBS.
Overall, the work reported here provides strong evidence that the LCP proteins,
in particular CpsA and Psr, play a major role in supporting GBS virulence by providing a
strong defense through synthesis of a robust cell envelope. These extracellular proteins
provide major targets for development of new antimicrobial strategies.
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INTRODUCTION

This chapter covers the most relevant and current information on Streptococcus
agalactiae, including modes of transmission, infection demographics, current
treatments, and their limitations; as well as virulence factors, cellular components that
can be used as therapeutic targets, and some of the genes that are involved in the
biosynthesis of these components.

1.1

Discovery of Streptococci
Streptococcus; from the Greek words: strepto, a chain, and coccus, a berry- was

first described in 1874 by Dr. Theodor Billroth, an Austrian surgeon. Dr. Billroth
described the microbe as small organisms which were isolated from wound infections
and were either single cocci or arranged in chains of two to twenty [1]. Streptococci
were formally introduced in 1879 by Louis Pasteur who isolated the bacteria from the
blood and uterus of women suffering from puerperal fever [1]. Two main ways of
distinguishing streptococcus species include the use of blood agar plates to differentiate
them into three groups of Alpha, Beta, and Gamma based on their hemolytic patterns;
and the use of surface antigens to divide them further into groups of A -X [2].

1.2

Streptococcus agalactiae
Streptococcus agalactiae (Group B Strep, GBS) is a Gram-positive, beta-hemolytic

bacteria that infects humans, cattle and fish. The organism was originally described in
1887 by Edmond Nocard as a cattle pathogen, causing bovine mastitis and
subsequently resulting in the lack of milk (agalactia) [3, 4]. In 1938, GBS was identified
as the source of puerperal sepsis and death in 3 patients at Queen Charlotte’s Maternity
1

Hospital in London [5]. In the succeeding decades, GBS continued to be identified as an
infectious agent, causing disease in pregnant women and infants, and emerged as the
leading cause of sepsis and meningitis in neonates in the 1970s [6].
1.2.1 Invasive GBS Infection in Adults
GBS is an asymptomatic colonizer of the gastrointestinal and reproductive tract
of 15-30% of the population [7-9]. However, it can cause invasive infection in pregnant
women, neonates, immunocompromised non-pregnant adults and the elderly with
underlying health conditions. Cases of invasive GBS (iGBS) infection in non-pregnant
adults are on the rise. In 2016 there were an estimated 35,000 iGBS cases in the United
States, up from an estimated 24,000 in 2008, with a mortality rate of 6.5% [10]. The
incidents of iGBS infection vary by age, gender, and race. The median age of iGBS
infection is 64 and 59% of reported cases were men compared to 41% women. Also,
there have historically been significantly more cases among African-Americans than
whites, though the difference has recently decreased due to an increase in cases
among whites. Ninety-five percent of invasive GBS disease occurs in individuals with at
least one underlying condition, most commonly obesity (53.9% of cases) followed by
diabetes (53.4%) [10]. Other common underlying conditions include atherosclerotic
cardiovascular disease, heart failure, and cancer. Two most common types of invasive
GBS disease in non-pregnant adults are skin and soft tissue infections (SSTIs) and
bacteremia. Other types include osteomyelitis, pneumonia, and septic arthritis [10].
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1.2.2 Invasive GBS Infection in Neonates
One of the more devastating incidences of GBS infection occurs in neonates.
There are two types of GBS infections in neonates; early onset infection, presenting
before seven days of age and late onset infection, which manifests between seven days
to three months of age. In early onset GBS disease, the organism is transmitted from
the mother’s genital tract to the baby, either by ascending infection in utero or during
labor by exposure to contaminated vaginal fluids. Up to 70% of neonates born to GBS
colonized mothers become asymptomatically colonized and of those, 1-3% develop
severe infections most commonly presenting as pneumonia and sepsis [11-14]. The
route of infection in late onset GBS disease is not always vertical (from mother to baby).
Although the baby may develop late onset GBS disease after being colonized during
labor, the disease can also be transmitted from the home or hospital environment, as
well as from contaminated breast milk. Late onset infection most commonly presents as
meningitis [8, 12, 14].
In order to prevent neonatal GBS infection, pregnant women are tested for GBS
colonization during the 35th-37th week of pregnancy and treated intravenously with
antibiotics during labor if found to be colonized [13]. Although this practice has lowered
the occurrence of GBS infection in more developed nations, it is not universally
practiced; therefore, many remain at risk. Additionally, fetal and neonatal exposure to
antibiotics has been shown to significantly affect the diversity and development of their
gut microbiota for the first several months of life, disturbing microbiota-induced host
homeostasis. The resulting dysbiosis in newborns may contribute to lifelong immune
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system deficiencies and conditions such as obesity, inflammatory bowel disease,
allergies, juvenile rheumatoid arthritis, wheezing and asthma [15-19].
1.2.3 Antibiotic resistance in GBS
The most common treatment for GBS infections are b-lactam antibiotics such as
penicillin and ampicillin [20]. Patients who are allergic to b-lactams are treated with
macrolides such as erythromycin, lincosamides such as clindamycin, or glycopeptides
such as vancomycin. Unfortunately, high percentages of GBS clinical isolates have
begun to show resistance or decreased sensitivity to these antibiotics [21, 22].
According to the Center for Disease Control and Prevention (CDC), clindamycin and
erythromycin resistant strains account for over 40% and 50% of GBS infections
respectively [23]. Additionally, clinical isolates with reduced sensitivity to ampicillin,
penicillin and vancomycin have recently been identified [20-22]. Furthermore, the
emergence of multi-drug resistant GBS isolates has posed a more serious problem for
combatting GBS infection.
With the rise in antibiotic resistance in bacterial pathogens, along with the risks
associated with neonatal antibiotic exposure and undetected GBS colonization,
developing alternative therapies is crucial. In searching for new therapeutic targets, it is
vital to understand GBS virulence factors and defense systems.
1.2.4 GBS Virulence Factors
Humans are typically asymptomatically colonized by GBS in the lower
gastrointestinal and genital tracts [24, 25]. In immunocompromised individuals and
neonates, however, GBS is introduced into the bloodstream and other organs, resulting
4

in systemic and invasive disease. GBS is normally found in the genitourinary tract,
which is a generally acidic environment in comparison to the bloodstream, where the pH
is more neutral. When GBS invades other parts of its host, such as the blood, lungs,
and the brain; the shift in environmental pH, nutrient levels, and varying immune
responses trigger the bacteria to switch from colonization-mode to survival-mode by
regulating a plethora of genes. Several studies have been performed to identify these
differentially expressed genes by incubating GBS in human whole blood and analyzing
global gene expression. Though extensive changes to the GBS transcriptome have
been demonstrated post whole blood incubation, [26, 27] these changes tend to differ
greatly depending on the GBS clinical isolate analyzed, making it difficult to make
general conclusions about differentially expressed genes in GBS. What is obvious, is
the incredible ability of GBS to transform and survive in these vastly different
environments by expression of several virulence factors [28] briefly described below.
One of the better understood virulence factors of Gram-positive bacteria,
including GBS, are pore-forming toxins, which are generally involved in the pathogen’s
dissemination through the body and its entry into host cells [29]. The two pore-forming
toxins that exist in GBS, are Christie Atkins Munch Peterson (CAMP) factor and βhemolysin/cytolysin. CAMP factor is a pore-forming secreted protein that functions by
associating with glycosylphosphotidylinositol-anchored (GPI) proteins of the host cells,
causing disruption of plasma membrane and cell lysis [30-32]. β-hemolysin/cytolysin (βH/C), is a multifunctional virulence factor that not only promotes invasion of epithelial
and endothelial cells of different host niches such as the Blood-Brain barrier [33] and
the lungs [34], but also induces host inflammatory response, leading to neurological,
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liver and cardiac dysfunction [35-37]. Expression of both CAMP factor and β-H/C is
regulated by extensively studied bacterial signal transduction systems, namely the
CovR/CovS two-component system [38, 39], though host environmental factors
triggering these regulations remain poorly understood.
One of the defense systems employed by host cells to combat pathogenic
invasion is the expression of cationic antimicrobial peptides (AMPs). AMPs are an
important part of the innate immunity in many organisms [40, 41]. Pathogens, including
GBS, however, have developed several mechanisms to bypass AMPs, such as
penicillin-binding proteins (PBPs), pili, and cell surface charge modifications. Pili are
small hair-like appendages that are present on many bacterial cell surfaces and are
generally regarded as facilitators of bacterial attachment to host cells [42]. In addition to
host cell adherence properties, GBS pili also increase resistance to phagocytes and
AMPs [7, 42-44]; though the mechanism for AMP resistance is not yet understood.
Although PBPs are generally known for their role in antibiotic resistance activity and the
synthesis of peptidoglycan [45-47], it is possible that one of these proteins in GBS,
PBP1a, helps promote AMP resistance through a yet unknown mechanism [48].
Bacterial cell surface charge modifications are important in AMP resistance. This is due
to the fact that AMPs are positively charged and create a strong interaction with
negatively charged bacterial cell surfaces. To counteract this, many bacteria, including
GBS, reduce their negative cell surface charge by integrating D-alanines into their cell
wall glycopolymers, thus creating a repulsion to positively charged AMPs [49-51].
Another series of GBS encoded virulence factors are those that promote bacterial
resistance to the host immune response and prevent bacterial recognition and
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destruction by the immune system. Noteworthy virulence factors in this category are:
cell-surface associated serine protease A (CspA), C5a peptidase (ScpB), superoxide
dismutase (SodA), and the sialic acid-rich capsular polysaccharide. The CspA protein is
a multifunctional protease, which cleaves the host (human) extracellular matrix protein,
Fibrinogen, preventing the host immune system from recognition and subsequent
phagocytic uptake of pathogenic GBS [52]. The second immune evasion mechanism
utilized by the CspA protein is the cleavage and inactivation of several chemokines
involved in the attraction and activation of neutrophils [53]. The immune system consists
of several chemoattractants such as the human complement component (C5a), which,
as implied by the name, are responsible for recruitment and activation of immune cells
such as neutrophils, monocytes, macrophages and T-lymphocytes [54]. GBS encodes a
C5a peptidase called ScpB, which cleaves C5a, hindering neutrophil recruitment to the
site of infection, leading to immune evasion by the pathogenic GBS [55-57]. Another
factor utilized by GBS is superoxide dismutase (SodA), which makes the bacteria more
resilient against oxidative stress caused by the production of reactive oxygen species
(ROS), which are produced by immune cells during infection [58, 59]. Perhaps the most
relevant GBS virulence factor in this dissertation is the sialic acid-rich capsular
polysaccharide, which envelopes the bacterial cells and prevents the immune system
from recognizing the bacteria as a foreign body, by mimicking the cell surface
component of the host cell, namely sialic acid residues present on mammalian cell
surfaces [60, 61]. The capsular polysaccharide will be addressed in more detail below.
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1.3

Peptidoglycan Cell Wall
Many factors play a role in peptidoglycan cell wall integrity, which is essential for

bacterial survival in all environments. Data presented in this dissertation and previously
in the Neely lab demonstrates the importance of several proteins in supporting cell wall
integrity, therefore the peptidoglycan cell wall will be briefly discussed here. The
cytoplasmic membrane of Gram-positive bacteria is surrounded by a thick
peptidoglycan cell wall, which helps regulate cell shape and osmotic pressure, and
protect the cell from environmental factors [62, 63]. The vital role of the peptidoglycan
cell wall in bacterial survival has made an optimal therapeutic target for some antibiotics
such as b-lactams and glycopeptides [64]. The basic building blocks of the cell wall are
completely conserved in Gram-negative and Gram-positive bacteria and are composed
of repeating N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc)
subunits. Although all peptidoglycan polymers are made up of these simple repeating
subunits, they are unique for each bacterial species through complex association
networks with multiple cell surface components. For instance, the repeating subunits
are crosslinked via pentapeptide chains with compositions that vary slightly across
species. The length of the glycan chains can also be substantially different between
bacterial species [64, 65]. The peptidoglycan cell wall also contains other components
such as proteins and glycopolymers, including teichuronic acids, wall teichoic acid
(WTA), and other anionic and neutral cell wall glycopolymers (CWGP). CWGPs are
involved in regulation of processes such as cell division, cell elongation, transport,
virulence and antibiotic resistance [64, 66-68].
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1.3.1 Peptidoglycan Cell Wall biosynthesis
Cell wall biosynthesis and assembly is an intricate process involving a complex
network of proteins and enzymes. Synthesis starts in the cytoplasm with the basic
building blocks of the peptidoglycan backbone, N-acetylglucosamine (NAG) and Nacetylmuramic acid (NAM) (Figure 1-1), which are linked through an ether bond. A
pentapeptide sidechain is then assembled onto the NAM residue in a series of
sequential steps catalyzed by Mur proteins [69, 70]. While the presence of NAG and
NAM as the core of the cell wall is conserved across all bacterial species, the sequence
of the peptide chain can vary between different species and even between different
strains of the same bacterial species. For instance, there are three different types of
peptide chains observed in Streptococcus pneumoniae; peptide chains without a side
branch and peptide chains that possess an L-Ala-L-Ala or an L-Ser-L-Ala side branch
[71]. Peptide chains are bound to each other directly or indirectly via transpeptidases
(PBPs) to create a flexible mesh-like structure [69-74]. Some of these modifications are
due to mutations that lead to bacterial resistance to cell wall targeting antibiotics.
1.3.2 Cell Wall Glycopolymer Biosynthesis
The bacterial cell wall consists of other components called cell wall
glycopolymers (CWGPs). Cell wall glycopolymers play a vital role in bacterial
physiology. They help in regulating cell morphology and division, regulating autolytic
enzymes, regulating ion homeostasis, aiding in the attachment of surface proteins,
protection against antibacterial molecules, and aiding in bacterial adhesion and
colonization. In Staphylococcus aureus, cells lacking CWGPs such as wall teichoic
9

acids (WTAs) have been reported to have increased cell size and irregularities in the
thickness of the peptidoglycan cell wall and the position of septum on the cell [75, 76].
Additionally, the lack of WTAs in some bacterial strains have led to increased autolysis
rates by changing endogenous autolysin expression [66, 77, 78]. WTAs also have the
ability to bind to protons and possibly facilitate localized pH changes and in turn
regulate the functions of certain enzymes under different pH conditions [77].
Two main classes of CWGPs are lipoteichoic acids (LTA) which are attached
directly to the cytoplasmic membrane via a glycolipid moiety, and wall teichoic acids
(WTA), which attach to the peptidoglycan cell wall, usually by a phosphodiester bond
[69]. Other CWGPs often present on bacterial cell walls include uncharged lipoglycans
and polyanionic teichuronic acids, among others. In general, CWGPs are made up of an
N-acetylglucosamine (NAG) and N-acetylmannosaminyl (MAN) backbone. MAN is then
decorated with repeating units of sugar alcohols (aditols) such as glycerol and ribitol,
though other non-sugar residues such as mycolic acids, pyruvate, phosphate, alanine,
or choline are also often present [67, 69, 71]. The type and composition of CWGPs
differ vastly across species [64, 79], but the most common repeating units are polyglycerophosphate [poly(Gro-P)] chains observed in Bacillus subtilis or polyribitolphosphate [poly (Rbo-P)] chains observed in Staphylococcus aureus [66, 69].
Interestingly, genome analysis of Streptococcus agalactiae (GBS) has not
detected any orthologues to gene loci involved in the biosynthesis of the common polyaditolphosphate WTAs [80, 81]. Rather, what has been detected, is an orthologue of
TarO/TagO, which likely encodes an enzyme that catalyzes the first step in WTA
biosynthesis. Previous reports suggest that the protein encoded by this orthologue,
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gbcO, is involved in the biosynthesis of Group B carbohydrate (GBC) antigen, a cell wall
glycopolymer specific to GBS [80, 82]. The GBC antigen is comprised of a Nacetylglucosamine (NAG) and N-acetylmannosaminyl (MAN) backbone, and repeating
oligosaccharide units that are arranged into 4 separate branches (Figure 1-1) [80].
Inactivation of gbcO results in a lack of GBC antigen production, and in turn leads to
conditions such as defects in peptidoglycan synthesis and assembly, abnormal cell
morphology and irregularities in cell division; all of which resemble the effects of CWGP
depletion in other bacterial species [82].
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Figure 1-1 Proposed peptidoglycan and wall glycopolymer biosynthesis pathways in
Streptococcus agalactiae
The left portion of the figure illustrates the peptidoglycan biosynthesis pathway in GBS, with the
production and assembly of UDP-GlucNac and UDP-MurNac, the assembly of the pentapeptide
attached to UDP-MurNac to create lipid I, and binding of UDP-GlucNac to create lipid II in the
cytoplasm. Lipid II is then transferred into the extracellular space, where Lipid IIs are bound to each
other via PBP enzymes and finally ligated onto existing peptidoglycan. The right portion of the figure
illustrates proposed biosynthesis of GBC antigen, starting in the cytoplasm with UDP-GlucNac and
ManNAc and the subsequent assembly of component oligosaccharides into 4 branches. Fully
assembled GBC is then transferred to the extracellular space ligated onto peptidoglycan via LCP
family proteins [80, 82]. This figure was adapted and modified from “Peptidoglycan Biosynthesis
Pathway in Streptococcus pneumoniae” using BioRender.com.
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1.4

Capsule
Gram-positive bacteria produce a long chain polysaccharide capsule that is

attached to the cell wall. The capsule is an important virulence factor and protects the
organism from biological, chemical, and physical stressors and plays a role in the
bacteria-host interaction, and immune evasion [83, 84]. One of the ways that capsule
protects the bacteria from the host immune system is by molecular mimicry of the host.
For instance, despite differences in components, all GBS capsular serotypes contain
terminal sialic acid residues, as also found on the surfaces of mammalian cells. Studies
have suggested that capsule-bound sialic acid in GBS provides protection against killing
by human platelets by interacting with immunoglobulin-like lectin (siglec-9) receptors
present on platelet surfaces [61, 85]. This leads to suppression of innate immune
responses such as phagocytosis, oxidative burst, formation of neutrophil extracellular
traps, and bacterial killing [61, 86].
GBS has 10 distinct capsular serotypes (Ia, Ib, II-IX) with different lengths and
sugar compositions. The gene products encoded by the cps locus, determine the
serotypes. The dominant serotypes causing disease vary regionally and differ by
invasive and colonizing isolates. For instance, in the United States, serotypes I-V
account for the vast majority (97-98%) of invasive GBS infections [87]. In neonates,
serotype III accounts for 43% of early onset and 73% of late onset GBS disease [88],
whereas non pregnant adults are most commonly infected with serotype V [89].
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1.4.1 Capsular polysaccharide biosynthesis
Capsular polysaccharide biosynthesis in GBS has not been fully studied but is
likely very similar to that of Streptococcus pneumoniae which has been characterized in
more detail [90]. Similar to the synthesis pathways of peptidoglycan and CWGPs,
capsule synthesis starts in the cytoplasm, where the basic repeating units are produced
and assembled by a network of glycosyltransferases. The fully assembled unit is then
attached to a membrane lipid and is transferred to the extracellular space via a flippase,
where it is further assembled into the full-length capsule, and is finally covalently bound
to the cell wall peptidoglycan [90]. In GBS, the first four genes of the CPS operon cpsAD are highly conserved across all serotypes. A proposed working model of CpsA-D has
been illustrated in figure 1-2.

Figure 1-2 The role of CpsA-D in Streptococcus agalactiae capsule biosynthesis.
(A) Illustrates the steps after capsular polysaccharide is transferred to the extracellular space. CpsH
polymerase attaches repeating units onto one another, then transferred to CpsC and is finally ligated
to the peptidoglycan cell wall via CpsA. (B) is a schematic representation of the working model
proposed for the CpsA-D proteins. Arrows, enzymatic reactions; bar-headed line, an inhibitory effect;
dotted line, an interdependency. [91] This figure is released under “Creative Commons CC-BY”
license.
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The CpsA protein is multi-functional with transcriptional activator activities [92]
and is believed to be the ligase that attaches the fully assembled capsule to the cell wall
[91]. CpsB and CpsC dephosphorylate and phosphorylate CpsD, respectively, and
CpsD phosphorylation determines capsular polysaccharide chain length. The other
genes of the operon encode serotype specific glycosyltransferases [91]. A
comprehensive list of cps operon genes and their respective functions is depicted in
figure 1-3.

Figure 1-3 Streptococcus agalactiae capsule operon
Arrangement of the polysaccharide capsule synthesis operon gene loci of GBS serotype Ia has been
illustrated above, with two putative promoter elements shown upstream of cpsA and cpsE
respectively. Capsule operon genes’ functions are also listed. Genes indicated via asterisks
demonstrate significant variation in sequence between GBS serotypes [93].
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1.5

LCP Family Proteins
The LCP (LytR-CpsA-Psr) family proteins have been studied in Gram-positive

bacteria for their role in peptidoglycan cell wall, cell wall glycopolymers and capsular
polysaccharide biosynthesis. Research has determined LCP protein involvement in
bacterial cell envelope maintenance and virulence [94, 95]. The LytR (lytic repressor),
CpsA (capsular polysaccharide expression regulator) and Psr (PBP 5 synthesis
repressor) are the three proteins recognized to contain a LytR domain. These proteins
are membrane bound and have a similar topology, comprised of a cytoplasmic Nterminus, 1-3 transmembrane domains which are essential for anchoring to the
membrane, and a long extracellular domain comprised of an optional accessory domain
and an obligatory LytR (LCP) domain (Figure 1-4) [95, 96].
LCP family proteins have been investigated in many bacterial species. In S.aureus,
there are three LCP proteins: LcpA, LcpB, and LcpC; which have been shown to have
specific functions, while being partially redundant [97, 98]. The LcpA and LcpB proteins
have been shown to influence WTA functions [99, 100]; whereas, the LcpC protein
plays a role in the attachment of capsule to the cell wall [101]. Deletions of lcp gene(s)
of S. aureus result in increased antibiotic susceptibility, changes in biofilm formation,
increased autolysis and changes in septum formation, and stress response [100, 102,
103].
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LCP Proteins’ Topology for Streptococcus pneumoniae

Figure 1-4 Protein topology of LCP family proteins in Streptococcus pneumoniae
Three members of the LCP family of proteins illustrated above, have been characterized in S.
pneumoniae. The Cps2A protein consists of a short intercellular N-terminus, three transmembrane
domains (blue) and a long extracellular region consisting of an accessory domain (red) and a LytR
domain (orange). Similarly, the Psr protein contains two extracellular domains, but only one
transmembrane domain . The LytR protein has a short intercellular N-terminus, one transmembrane
domain, and just a LytR domain in the extracellular region [104]. This figure is released under
“Creative Commons CC-BY” license.

1.5.1 CpsA
cpsA is the first gene in the capsule (cps) operon, and regulates the transcription
of cpsB, cpsC, and cpsD genes [91, 92]. The CpsA protein is a member of the LCP
family and is 485 amino acids long in GBS. The protein structure consists of a short Nterminal cytoplasmic region, followed by three transmembrane helices and a long
extracellular domain. (Figure 1-4). The first transmembrane region contains a putative
leucine zipper motif (Neely lab, unpublished). The CpsA protein also has a long
extracellular portion spanning approximately 400 amino acids and consists of two
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separately folding domains, Accessory and LytR domains. As illustrated in figure 1-3,
the GBS capsule operon contains two promoters: one upstream of cpsA and another,
upstream of cpsE. Electromobility Shift Assay (EMSA) experiments demonstrated that
the cytoplasmic N-terminus of CpsA has DNA binding sites, where it binds to both
promoters [92]. EMSAs using a purified CpsA protein with its entire extracellular region
missing indicated that the protein still binds to both promoter regions of the capsule
operon, but with reduced specificity. This suggests that although the extracellular region
is not required for DNA binding, it does have a role in binding specificity [92]. Another
set of EMSAs were performed using a purified CpsA protein consisting of only the Nterminus and the first transmembrane loop, which has the leucine zipper motif. This set
of experiments also revealed that the construct does bind to both promoter regions but
also with reduced specificity [92], indicating once again that only the N-terminus and the
first transmembrane loop are required for DNA binding and interaction, but other
transmembrane and extracellular portions aid in specificity of those interactions,
possibly by providing the correct conformation.
A truncated cpsA construct missing only the extracellular LytR domain
overexpressed from a plasmid in both the wild-type and DCpsA GBS strains
demonstrated a significant reduction in capsule levels. This demonstrated that the
truncated CpsA could not complement the ΔCpsA strain to produce a capsule. More
importantly, even when the cpsA gene was being expressed from the chromosome in
the wild-type strain, capsule levels were still reduced. These results showed that the
extracellular accessory domain that was still present in this construct has a dominant
negative effect over the wild-type CpsA protein, resulting in decreased capsule
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production [92, 105]. Further investigation pinpointed this dominant negative effect to be
the result of the presence of a region found in the CpsA protein that had a disordered
loop region that could not be modeled in the crystallographic depiction of the protein
[104]. This region is found in the inter-domain region (amino acid 210-245) between the
accessory domain and the LytR domain (Figure 1-5) [105]. Surprisingly, addition of a
synthesized peptide with the sequence corresponding to this region into cultures with
the wild-type GBS strain also resulted in a reduction in capsule levels and formation of
longer chain lengths and [105].
Previous studies demonstrate that CpsA orthologues: Cps2A in S. pneumoniae
and LcpC in S. aureus, function as ligases that attach the capsular polysaccharide onto
the cell wall, and the deletion of the genes encoding these proteins leads to decreased
capsule production in both bacterial species [96, 101, 106]. Recent findings in our lab
supports the idea that CpsA in GBS plays the same role. Deletion of cpsA results in
formation of long chains and decreased capsule production, suggesting that the CpsA
protein is involved in both capsule expression and cell wall integrity [92]. The role of
certain domains of CpsA, such as the extracellular accessory domain and the leucine
zipper motifs within the transmembrane domain remain to be determined.
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Figure 1-5 CpsA topology in Streptococcus agalactiae
CpsA is a transmembrane protein consisting of a short N-terminus cytoplasmic region, 3
transmembrane domains the first of which contains a putative leucine zipper motif, and a long
extracellular region consisting of the accessory domain and the LytR domain separated by an interdomain region of approximately 21 amino acids long. This figure was created via BioRender.

1.5.2 LytR (BrpA)
The LytR protein, also called BrpA (Biofilm Regulatory Protein A) [72], is another
member of LCP family proteins in GBS. Deletion of LytR in GBS resulted in a biofilm
defect, increased cocci chain length, and increased susceptibility to neutrophil killing in
both murine and human blood. The knockout strain also proved to be less effective in
vaginal colonization and sepsis in murine models. Additionally, RNA-seq data shows
significant differences in cellular metabolism and cell wall synthesis pathways of ΔlytR
and wild-type GBS strains [72]. In S .pneumoniae, ΔlytR strains do not easily grow in
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culture, suggesting that lytR is a housekeeping gene and is essential for viability of the
bacteria. A brpA deletion in Streptococcus mutans leads to a negative effect on acid
tolerance, autolysis, cell division and cell envelope and biofilm formation [107].
1.5.3 Psr
The Psr protein has been investigated in bacterial species such as S. mutans and
S. pneumoniae [104, 107]. Psr protein deficiency in S. mutans has a negative effect on
acid tolerance, autolysis, cell division and cell envelope and biofilm formation, similar to
the effects of a brpA deletion [107]. Perhaps most interestingly, Psr protein deficiency in
S. mutans leads to a decrease in glycotransferase C expression and in turn decreases
glucan formation [107]. In S .pneumoniae, the Psr protein, along with the Cps2A and
LytR proteins, localize at the cell surface and especially at the septum. This indicates
that as hypothesized, the Psr protein and its homologs play a role in cell wall
maintenance and cell division. Deletion of the psr gene leads to reduced capsule
production in S. pneumoniae [104]. The exact role of the Psr protein in GBS has not yet
been determined. Chapter 2 of this document will show the results of our investigation
into the possible role of this protein in capsule production, cell wall integrity, antibiotic
susceptibility and virulence in zebrafish.
As previously mentioned, there are major shortcomings in current treatments for
infections caused by GBS due to several factors such as the risk of GBS colonization
going undetected before labor, along with the rise in antibiotic resistance in bacterial
pathogens including GBS, and the known risks associated with the exposure of
neonates to antibiotics. Much work has been done to understand and characterize
virulence factors of Gram-positive bacteria including GBS, in hopes of finding new
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therapeutic targets and ultimately developing new drugs and vaccines. The work
presented in this dissertation has been aimed to better characterize two GBS LCP
family proteins, CpsA and Psr.
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2

THE LCP FAMILY PROTEIN, PSR, IS REQUIRED FOR CELL WALL INTEGRITY
AND VIRULENCE IN STREPTOCOCCUS AGALACTIAE

This chapter represents a modified form of the published work from: Rajaei, A, Rowe,
HM, and Neely, MN.(2022). The LCP family protein, Psr, is required for cell wall
integrity and virulence in Streptococcus agalactiae. Microorganisms, 10(2),
217; https://doi.org/10.3390/microorganisms10020217

2.1

Chapter Summary
A robust cell envelope is the first line of protection for an infecting pathogen when

encountering the immune defense of its host. In Gram-positive organisms, LytR-CpsAPsr (LCP) family proteins play a major role in the synthesis and assembly of the cell
envelope. While these proteins could be considered for potential new drug targets, not
enough is known about how they function to support the integrity of the cell wall.
Streptococcus agalactiae (group B streptococcus or GBS) is known to encode at least
three LCP family proteins, including CpsA, LytR (BrpA), and Psr. Using strains of GBS
that have mutations in two of the three LCP proteins, we were able to determine a role
for these proteins in GBS cell wall integrity. The results presented here demonstrate
that the absence of Psr results in a decreased growth rate, decreased viability over
time, inconsistent cocci morphology and diminished cell wall integrity, as well as an
increased penicillin susceptibility, decreased capsule levels and attenuation in virulence
in a zebrafish model of infectious disease. A strain that is missing two of the LCP family
proteins, CpsA and Psr, exhibits an increase in these defective phenotypes, indicating
that CpsA and Psr are partially redundant in function.
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2.2

Introduction
Streptococcus agalactiae (GBS) is a commensal organism that is typically present

in the lower gastrointestinal and reproductive tract of 15-30% of individuals [7-9]. It can
cause invasive infection in the most vulnerable groups of the population including the
elderly, adults with compromised immune systems and other underlying health
conditions, and perhaps most devastatingly in neonates. GBS is the leading cause of
sepsis and meningitis among newborns due to their underdeveloped immune system at
birth. GBS infections in newborns are classified into two different forms based on time of
onset; early-onset disease occurs within the first 7 days of life, whereas late-onset
disease occurs within 7-90 days after birth and is most commonly transferred from the
colonized mother to baby during pregnancy or labor [108]. The current preventative
measure for neonatal GBS disease is screening pregnant women for GBS colonization
during weeks 35-37 of pregnancy and intravenous administration of antibiotics to the
colonized mother during labor [13]. Though this practice has dramatically reduced the
occurrence of early-onset GBS disease, it does not prevent late-onset GBS infection as
it is not always transmitted from colonized mother during labor, but rather is acquired in
the hospital or through community transmission [28, 108]. Additionally, studies have
shown that exposure to antibiotics during infancy, dramatically affect the gut microbiota
and may lead to lifelong immune system deficiencies and conditions such as obesity,
inflammatory bowel disease, allergies, juvenile rheumatoid arthritis, wheezing and
asthma [15-19]. Moreover, multiple GBS clinical isolates have become resistant to
specific antibiotics [20-23], causing concern about the future of GBS infection treatment.
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For these reasons, there is an urgent need for development of new therapeutic
strategies to help combat GBS infections.
Development of new antimicrobials requires identification and mechanistic
understanding of new bacterial targets. The LytR-CpsA-Psr (LCP) family of proteins are
potential antimicrobial targets for Gram-positive pathogens including GBS. LCP proteins
have been extensively studied in pathogens such as Staphylococcus aureus,
Streptococcus pneumoniae, and Streptococcus mutans; and are involved in
biosynthesis and maintenance of the cell wall and capsule [95, 97, 104, 107]. Three
LCP proteins LcpA, LcpB, and LcpC have been characterized in S. aureus and have
been shown to be partially compensatory in function [102]. LcpA and LcpB are both
involved in the attachment of wall teichoic acids (WTA) to the peptidoglycan cell wall
[99, 100], while LcpC has been characterized as ligating the capsular polysaccharide to
the cell wall [101, 102]. In S. pneumoniae, there have also been three LCP family
proteins characterized, Cps2A, LytR, and Psr, which are partially redundant in function.
Single deletions of cps2A and psr in S. pneumoniae lead to decreased capsule
production, while lytR deletion is deadly [104, 109, 110]. GBS also has three LCP
proteins, CpsA, LytR (BrpA), and Psr. CpsA is a transcriptional regulator of the capsular
polysaccharide (cps) operon [91, 92] and is also proposed to be the ligase that attaches
newly assembled polysaccharide capsule onto the cell wall [96, 104]. LytR, also known
as biofilm regulatory protein (BrpA) in GBS regulates biofilm formation and influences
GBS virulence [72]. Psr in GBS is not yet well characterized. In S. mutans, however, it
affects autolysis, acid tolerance, biofilm formation and cell division [107, 111-113]
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In this study, we demonstrate the role of Psr in the maintenance of cellular
morphology, cell wall integrity, and virulence of GBS. Loss of Psr results in a growth
deficiency, increased autolysis in the presence of compounds that disrupt structural
integrity, decreased capsular polysaccharide on the cell surface and attenuation of
virulence in a zebrafish model of infectious disease.

2.3

Materials and Methods

2.3.1 Bacterial strains and growth conditions
The streptococcal strains Streptococcus agalactiae GBS 515 and the CpsA
deletion strain (DCpsA) were described previously [92, 114]. Streptococcal liquid
cultures were grown statically in closed tubes in THY medium (Todd Hewitt Broth
(Acumedia) +0.2% yeast extract at 37˚C. The Psr mutant and the CpsA-Psr double
mutant strains were supplemented with erythromycin (2μg/mL). The Psr mutant strain
(DPsr) was constructed by amplifying a 490 bp region of GBS 515 genomic DNA using
primers (5’ GBS Psr ins EcoRI CCGGAATTCGCTAAATCATCATGAAGAGC- and 3’
GBS Psr ins PstI- AAAACTGCAGTTAAGCTCCCATCAACAGC) and ligated into the
EcoRI and PstI sites of plasmid pUC19-Erm [115]. The plasmid was electrotransformed
as described previously into GBS 515 and its isogenic DCpsA strain [114]. Single
crossover recombinants were selected by growth on erythromycin (2 ug/ml) on THY
(Acumedia) agar plates supplemented with 0.2% yeast extract and 1.4% bacteriological
agar (Acumedia).
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2.3.2 Growth curve
Overnight cultures were subcultured 1:100 into 20ml of fresh THY medium and
grown statically at 37°C. Growth of cultures were monitored by measuring and recording
the OD600 once every hour for 10 hours using a spectrophotometer (Beckman Coulter,
PU530). Values represented are averages of 3 biological replicates.
2.3.3 Antibiotic assay
Overnight cultures were subcultured 1:100 in 20ml of fresh Todd Hewitt Broth
(Neogen) +0.2% yeast extract (VWR) and normalized to 0.01 OD600. Cells (150 µL)
were added to clear, flat-bottom 96 well plates in triplicate and supplemented with 0
µg/mL (untreated) and 0.03 µg/mL of penicillin. Plates were sealed and incubated at
37°C for 24 hours. Contents of each well were mixed by pipetting, then OD600
measurements were taken via plate reader (Bio Tek, Synergy 2). Viable counts were
determined by plating serial 10-fold dilutions of samples 24 hours post treatment, on
THY-agar plates. Values represented are averages of 4 biological replicates.
2.3.4 Live/Dead assay
The live/dead assay was performed according to LIVE/DEAD™ BacLight™
Bacterial Viability Kit (Invitrogen L13152) protocol. Briefly, cells at mid-log growth phase
(0.3 OD600) and at stationary growth phase (overnight cultures) were collected and
washed once and resuspended in 0.85% NaCl. Five microliters of cells and 5 µL of 2X
stain were thoroughly mixed by pipetting and incubated at room temperature for 15
minutes while protected from light. Stained cells (7 µL) were pipetted onto a glass slide
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with a coverslip and observed via fluorescent microscopy using Zeiss Axioscope 40 and
a FITC filter at 1000X magnification and imaged with Axiovision 4.7 imaging software.
Images were quantified by recording chain lengths for each strain using 10 fields of view
per sample.
2.3.5 Sonication
Overnight cultures were sub-cultured and grown statically at 37°C. Cells were
collected at mid-log growth phase and normalized to 0.3 OD600 in PBS (phosphate
buffered saline, pH 7.4). Cells were sonicated via (Fisher scientific sonic dismembrator
60) at level 2 (4 Watts) for 6 seconds on ice. Serial 10-fold dilutions were plated on
THY-agar plates and compared to untreated cells.
2.3.6 Triton X-100 susceptibility
Overnight cultures were subcultured and grown statically at 37°C. Cells were
collected at mid-log growth phase and normalized to 0.3 OD600 in PBS. Samples were
treated with 0.01% final concentration of Triton X-100 (Fisher bioreagents) in PBS for 2
hours at 37°C. Serial 10-fold dilutions were plated on THY-agar plates, incubated at
37˚C overnight and compared to untreated cells. Values represented are averages of 6
biological replicates.
2.3.7 Lysozyme susceptibility
Overnight cultures were subcultured and grown statically at 37°C. Cells were
collected at mid-log growth phase and normalized to 0.3 OD600 in PBS. Samples were
treated with 1mg/mL final concentration of lysozyme (Sigma, L6876) in PBS for 24
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hours. Serial 10-fold dilutions were plated on THY-agar plates, incubated overnight and
compared to untreated cells. Values represented are averages of 4 biological
replicates.
2.3.8 Capsule measurement by ELISA
Secondary antibody was pre-cleared as follows: 2.5mL of WT and DCpsA
overnight cultures were centrifuged, resuspended in 1mL Tris-buffered saline (TBS) and
treated with 1:100 final concentration of goat-anti-rabbit IgG-AP (Invitrogen,65-6122) at
4°C for 1 hour on rotator. Cells were then pelleted by centrifugation and supernatant
was filtered using a 0.22µm (Sterlitech) and kept refrigerated until use.
Overnight cultures were normalized to 0.75 OD600, washed and resuspended in
TBST (Tris-buffered saline + 0.1% Tween 20) and treated with 1:10,000 final
concentration of primary antibody (Rabbit a-serotype 1a GBS) at 4°C for 1 hour on
rotator. Cells were washed 3X with TBST and resuspended in 1mL TBST and
supplemented with 20µL pre-cleared secondary antibody for a final concentration of
1:5,000 at 4°C for 1 hour on rotator. Cells were washed 3X with TBS and resuspended
in 1mL TBS. Cells (50µL) were aliquoted in triplicate in 96 well clear, flat-bottom plate at
the following dilutions, undiluted, 1:2 dilution and 1:4 dilutions, along with cells treated
only with 2° antibody as control. Cells were supplemented with 150 µL pnpp buffer +
phosphatase substrate tablets (Sigma, S0942). Plate was sealed and incubated at room
temperature for 1 hour in dark. Assay results were measured spectrophotometrically
(OD405 and OD600) via plate reader (BioTek, Synergy 2) and AP (alkaline phosphatase)
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unites were calculated using the following formula: ('() + , + !"-$$) 𝑥 1000 = 𝐴𝑃 𝑢𝑛𝑖𝑡𝑠 .
Values represented are averages of 6 biological replicates.
2.3.9 Capsule measurement by Buoyant density
Buoyant density was determined using linear Percoll (GE Healthcare) gradients
as described previously [116]. Briefly, 4mL Percoll, supplemented with 0.15M NaCl,
diluted to low (1.085 g/cm3) density was carefully overlaid onto 4mL Percoll diluted to
high (1.120 g/cm3) density in a 10mL tube and placed at a 15° angle overnight to allow
formation of a continuous linear gradient. Next day, gradients were gently placed
vertically and allowed to settle at least 30 minutes prior to centrifugation. Overnight
bacterial cultures were normalized to an 0.6 OD600 in 1ml and concentrated to a
volume of 100μL in phosphate buffered saline. Culture was carefully added to top of
gradient and gradients were centrifuged 30 min at room temperature at 5,000 rpm in a
swinging bucket (Eppendorf Centrifuge 5403 with Rotor 16A4-44). Distance traveled in
the gradient was measured from the bottom of the meniscus to the center of the cell
band, and density was determined by calculation of a linear curve from distance
traveled by beads of known density (GE Healthcare). Values represented are averages
of 3 biological replicates.
2.3.10 Measurement of capsule in supernatants
Overnight cultures were subcultured and grown statically at 37°C. Cells were
collected at mid-log growth phase and normalized to 0.3 OD600 in TBS. Culture
supernatants were serially diluted and 5µls were pipetted onto 0.45μm PVDF
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membrane (Ultra Cruz) and allowed to air dry. The membrane was then treated with 5%
blocking buffer at 4°C for 1 hour on an orbital shaker. Membrane was then treated with
5% blocking buffer + 1:10,000 final concentration of primary antibody (Rabbit α-GBS
serotype 1a) at 4°C overnight on an orbital shaker. The next morning, the membrane
was washed 3X with TBST for 5 minutes each, then treated with 5% blocking buffer with
a 1:5,000 final concentration of goat anti-rabbit IgG-AP (Invitrogen) for 1 hour, then
washed again 3X with TBST for 5 minutes each. The membrane was then treated with
4ml BCIP/NBT substrate (Sigma, B3679) until spots became visible. Experiment was
repeated 3 times.
2.3.11 Chain length analysis
Overnight cultures were pipetted onto a microscope slide with a coverslip and
observed using a Zeiss Axioscope 40 bright field microscopy at 1000X magnification
and imaged with Axiovision 4.7. Chain lengths were quantified using 10 fields of view
per sample. A minimum of 2,500 cocci per strain were quantified.
2.3.12 Fluorescent Vancomycin Assay
Overnight cultures were subcultured and grown statically at 37°C. Cells were
collected at mid-log growth phase and normalized to 0.3 OD600 in PBS and
concentrated to 1.0 OD600. Ten microliters of samples were treated with 1µg/µL
BODIPY_FL vancomycin (Life Technologies) and incubated for 10 minutes at 37°C
while protected from light. Treated samples were then washed 3X with PBS and
resuspended in 3µL PBS. Samples were observed and imaged using confocal
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microscopy. Micrographs are representative of at least 15 images per strains, recorded
from 2 biological replicates.
2.3.13 Zebrafish infection
Cells were collected at mid-log growth phase, normalized to 0.225 OD600 (~1 x
108 cfu/ml) and washed 2X with PBS. Zebrafish (Zf5) were anesthetized with
0.32mg/mL tricaine and injected at 72 hours post fertilization with 1 nano-liter (~100 cfu)
of bacteria in the yolk sack. Injections were performed via PV830 pneumatic picopump
microinjector (World Precision Instruments) and Stemi 508 microscope. Fish were then
observed for 72 hours for survival post infection. Dosages were verified by plating serial
10-fold dilutions of 100 cfu samples. All experiments were carried out according to the
University of Maine IACUC committee approved protocol A-2020-02-01. Values
represented are averages of 4 biological replicates with a minimum of 105 total
zebrafish injected per strain.
2.3.14 Statistical Analysis
Statistical analysis for triton X-100 induced autolysis, lysozyme induced autolysis,
Penicillin susceptibility and buoyant density assays was conducted using Microsoft
Excel data analysis tool, by first conducting an F-test to determine variance followed by
a T-test to determine significance. P < 0.05. Statistical analysis for zebrafish infection
was conducted using Prism 9 version 9.1.2 log-rank (Mantel-Cox) test.
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2.4

Results

2.4.1 Loss of Psr results in a growth deficiency
As LCP proteins are suggested to play a role in cell envelope synthesis and
maintenance [96, 104, 107], we wanted to determine if strains lacking Psr exhibited a
change in overall cell growth. The growth rate of the wild-type GBS, ΔCpsA, ΔPsr and
ΔCpsA-ΔPsr strains in THY liquid culture was determined. While wild-type GBS and
ΔCpsA GBS strains grow similarly, the ΔPsr and ΔCpsA-ΔPsr mutant strains grow at a
considerably slower rate (Figure 2-1). When comparing the ΔCpsA and the ΔCpsA-ΔPsr
mutant strains, while the growth of the ΔCpsA strain is not affected, the double mutant
strain shows the slowest growth rate of all four strains. These results suggest that in the
absence of Psr, CpsA may be partially substituting for its functions; therefore, in the
absence of both genes, growth rate substantially decreases.
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GBS Growth Curve
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Figure 2-1 GBS growth decreases in the absence of Psr.
Overnight cultures were sub-cultured 1:100 in fresh media and grown statically at 37°C. OD600 was
measured via spectrophotometer. WT GBS (green) and DCpsA GBS (red) grow at a similar rate.
DPsr (yellow) and DCpsA-DPsr (blue) grow at a decreased rate, with the double mutant’s growth
most affected. Graph is representative of 3 separate growth curves.

2.4.2 CpsA-Psr Double Mutant strain is significantly less viable over time
To determine if the decreased growth rate observed with the ΔPsr and ΔCpsAΔPsr mutants is a result of missing components needed for cell growth or a loss of
viability of cells overtime, Live/Dead assays were performed on all strains at mid-log
and stationary phase of growth. The Live/Dead assay determines cell viability as a
function of membrane integrity of the cell. Therefore, live cells stained in this assay
fluoresce green from the SYTO9 dye, while cells that are thought to be dead or dying
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will stain red from propidium iodide. Although no significant cell death was observed at
mid-log growth phase (Figure 2-2A and 2-2C) for any of the four strains, a surprising
41% cell death was observed for the ΔCpsA-ΔPsr double mutant strain at stationary
phase (Figure 2-2B and 2-2C).
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WT

ΔCpsA

ΔPsr

ΔCpsA-ΔPsr

Figure 2-2 GBS cell viability is significantly affected at stationary phase.
GBS strains were grown to mid-log and stationary phase in THY medium, normalized to OD600: 0.6
in 0.85% NaCl, and treated with live/dead stain. (A) Images of cells grown to mid-log phase where
green cells represent live cells and red cells represent dead cells. (B) Images of cells grown to
stationary phase where green cells represent live cells and red cells represent dead cells. (C)
Percentage of live cells were quantified. Micrographs of each strain were imaged and 10 fields of
view per strain were used to quantify percent live cells.
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Figure 2-2 Continued
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∆CpsA-Psr

2.4.3 Loss of CpsA and Psr results in an increase in Bacterial Chain Length
The Psr protein is thought to be directly involved in the production of the
peptidoglycan cell wall and an increase in chain length has been associated with cell
wall abnormalities [107]. In order to determine if the absence of Psr would result in a
change in cocci chain length in GBS, cultures were visualized using bright field
microscopy and chain lengths of each strain were quantified. Chain length analysis
revealed that the wild-type strain normally grows as chains of 2-6 cocci with a mean
value of 2.5, while the majority of the chains in the ΔCpsA strain normally have of 2-10
cocci with a mean value of 4.0 (Figure 2-3A and 2-3B). The ΔPsr mutant strain exhibits
longer chain lengths of about 6-30 cocci with a mean value of 12.9, while the double
mutant demonstrates chain lengths of as long as 70 cocci with a mean value of 20.4
(Figure 2-3A and 2-3B).
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A
WT

ΔCpsA

ΔPsr

ΔCpsA-ΔPsr

B

Figure 2-3 GBS chain length increases in the absence of CpsA and Psr.
Overnight cultures were mounted on microscope slides and visualized via brightfield microscopy. (A)
Micrograph images of each of the 4 GBS strains pipetted onto a glass slide. (B) A quantitative
representation of the chain length analysis. Images using 10 fields of view from each strain were
used to quantify the number of cocci in each chain, with green line indicative of median chain length.
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2.4.4 Loss of Psr results in changes in cell wall integrity
To determine if the absence of the Psr protein from the cell causes a change in
cell wall morphology, fluorescent vancomycin assays were performed. Fluorescent
vancomycin binds to newly formed cell walls and is a green fluorescent analog of
vancomycin allowing visualization of cell morphology using fluorescent microscopy.
Observation of the cells tagged with fluorescent vancomycin revealed a possible
change in cell wall integrity in all mutants, but most notably in the ΔPsr and ΔCpsA-ΔPsr
mutant strains. Since the tagged fluorescent dye binds to the cell wall, an intact cell wall
would only stain around the outside of the cell. If the stain is observed inside the cell,
then this suggests a loss of cell wall integrity allowing the dye to leak into the cell. The
wild-type and the ΔCpsA strains show cocci defined as an open circle, indicating the
stain only attached to the cell wall (Figure 2-4). However, the ΔPsr and ΔCpsA-ΔPsr
mutant strains show cocci that have stain completely filling the interior of the cell,
indicating that the stain has leaked inside the cell. Additionally, we observed areas in
which cocci appeared to be deformed in both ΔPsr and ΔCpsA-ΔPsr strains, suggesting
that cell wall integrity defects may cause morphology changes (Figure 2-4).
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WT

ΔCpsA

ΔPsr

ΔCpsA-ΔPsr

Figure 2-4 Bacterial cocci morphology changes in the absence of Psr.
Overnight cultures were incubated with fluorescent vancomycin and imaged via confocal
microscopy. WT and the ΔCpsA strains exhibit shorter chains, uniform cocci morphology and intact
cell walls, while the ΔPsr and ΔCpsA-ΔPsr mutant strains exhibit longer chain lengths, leaky cell
walls and anomalous cell morphologies. Micrographs are representative of images recorded from 2
assays repeated on 2 different days.

2.4.5 Loss of Psr results in increased Autolysis
Lcp family proteins have been shown to protect against autolysis. In
Staphylococcus aureus for instance the deletion of the sa0908 gene led to increased
triton X induced autolysis [102]. Since a possible change in cell wall integrity was
observed with the fluorescent vancomycin assay, several experiments were performed
to determine if loss of the Psr protein would make the cells more susceptible to
autolysis. Triton X-100, a typical non-ionic detergent and works by breaking lipid-lipid or
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lipid-protein associations, was used to examine the integrity of the cell walls of the four
GBS strains. Exposure of log phase growth cells to 0.01% triton X-100 for 2 hours
resulted in the ΔPsr and ΔCpsA-ΔPsr mutant strains revealed an increased sensitivity to
triton X-100 induced autolysis (Figure 2-5A). Log killed values were determined by
comparing the final growth of the untreated culture to the final growth of the culture with
treatment of the same strain, thus accounting for the differences in growth of each
strain. The ΔPsr mutant and ΔCpsA-ΔPsr mutant strains demonstrated a log killing
of 3.61 and 4.12 respectively, compared to 3.33 and 3.32 for the wild-type and ΔCpsA
strains (Figure 2-5B). Therefore, the simultaneous absence of CpsA and Psr results in a
significant decrease (p < 0.05) in cell integrity when exposed to triton X-100.
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Figure 2-5 GBS autolysis increases in the presence of triton X-100
GBS strains were grown to mid-log in THYB, normalized to OD600: 0.3 in PBS and treated with
0.01% Triton X-100 for 2 hours. (A) Treated (Red) and untreated (Blue) samples were then serially
diluted and plated on THY plates. Statistical analysis represents significance between untreated and
treated cells for each strain. (B) Log CFU killed was calculated for each sample by taking log10
(untreated/treated). Significance was determined by comparing log CFU killed of each strain to that
of wild-type GBS. (C) 5μL of serial dilutions of treated cells were dotted on THY plates and grown
overnight for visual representation of treatment outcomes. Values represented are averages of 6
biological replicates. * P < 0.05
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A second method used to examine cell wall integrity was exposure of all strains
to lysozyme. Lysozyme cleaves peptidoglycan in bacterial cell walls by catalyzing the
hydrolysis of β-(1,4) linkages between the NAM and NAG saccharides. Treatment of log
phase growth cultures with 1mg/ml lysozyme for 24 hours demonstrated that lysozyme
has an effect on all four strains (Figure 2-6A). However, the ΔPsr and ΔCpsA-ΔPsr
mutant strains are significantly (p < 0.05) more sensitive to lysozyme (Figure 2-6B). As
with the Triton X-100 treatment above, log killed values were determined by comparing
treated to untreated growth of each strain against itself to account for difference in strain
growth. Lysozyme treatment revealed log killed values of 3.84 and 4.31 for the ΔPsr
and ΔCpsA-ΔPsr mutant strains respectively, compared to 2.22 and 2.62 for the wildtype and ΔCpsA strains, demonstrating that the absence of the Psr protein results in a
loss of cell wall integrity (Figure 2-6B). Subinhibitory concentrations of other agents
such as EDTA, tween-20 and mutanolysin were also tested on all four strains with no
significant effect of autolysis (Data not shown).
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Figure 2-6 GBS autolysis increases in the presence of lysozyme.
GBS strains were grown to mid-log in THYB, normalized to OD600: 0.3 in PBS and treated with
1mg/mL Lysozyme for 24 hours.(A) Treated (Red) and untreated (Blue) samples were then serially
diluted and plated on THY plates and counted. Statistical analysis represents significance between
untreated and treated cells for each strain. (B) Log CFU killed was calculated for each sample taking
Log10 (untreated/treated). Significance was determined by comparing log CFU killed of each strain
to that of wild-type GBS. (C) 5μL of serial dilutions of treated cells were dotted on THY plates and
grown overnight for visual representation of treatment outcomes. Values represented are averages
of 4 biological replicates. * P < 0.05
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2.4.6 Sonication Causes Cell Lysis in Psr Mutants
In order to address decreased growth of the DPsr and the DCpsA-DPsr mutant
GBS strains in liquid culture and on THY plates, we examined the possibility that due to
longer chain length and decreased number of chains, there may be fewer colony
forming units in the culture. Cells were sonicated on low settings and short duration to
avoid cell lysis. Sonicated and un-sonicated cells of the same concentration were
serially diluted and plated. Results from this experiment (figure 2-7) illustrate no
significant changes in colony forming units, suggesting chain length has no effect on the
number of colonies that grow on the plate.

GBS survival post sonication
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Figure 2-7 Effect of sonication on GBS growth
Cells were grown to mid-log and normalized to OD600: 0.3 in 0.85% NaCl. Aliquots of un-sonicated
cells were set aside for plating, and the remaining of the cell suspensions were sonicated at 4 watts
for 6 seconds. Samples were then serially diluted and plated in THY plates. As expected, untreated
DPsr mutant cells grew less overnight in comparison to WT and DCpsA GBS cells (purple). Growth
did not improve post sonication with the conversion of long chains to shorter chains (Blue).
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To confirm that sonication does not result in lysis of the cells, a live/dead assay
was performed post sonication. Interestingly, while in WT and DCpsA strains sonication
led to production of shorter chains without any significant cell lysis, sonication of the
DPsr and the DCpsA-DPsr strains led to shorter chains, but also a considerable amount
of cell lysis, as illustrated in figure 2-8. These results support the idea that Psr is an
important component of the cell wall biosynthesis process and without it the GBS cell
wall integrity and strength are greatly reduced.
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ΔCpsA-ΔPsr

Figure 2-8 Live-Dead assay on GBS strains post sonication
Live/Dead assay was performed on cell suspensions pre and post sonication. While WT and DCpsA
chain lengths were reduced without any significant cell lysis, DPsr and DCpsA-DPsr strains exhibit
considerable cell lysis even in low sonication levels and duration.
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2.4.7 Absence of CpsA and Psr result in increased susceptibility to penicillin
LCP proteins have been previously shown to have an effect on antibiotic
susceptibility in Gram-positive bacteria [117], therefore, the effect of Psr protein
absence on penicillin susceptibility was examined. Penicillin is a b-lactam antibiotic and
is one of the main antibiotics used to treat GBS infections Assay results demonstrate
that in the absence of Psr, GBS becomes more susceptible to penicillin compared to
wild-type GBS (Figure 2-9A). Log killed values were 3.98 and 4.13 for the ΔCpsA and
the ΔPsr mutant strains respectively, which are significantly more (p < 0.05) than that of
the wild-type strain at 2.28. The ΔCpsA-ΔPsr double mutant strain demonstrates the
highest amount of cell death with a log killed value of 5.05, after penicillin exposure (p <
0.005) (Figure 2-9B).
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Figure 2-9 GBS susceptibility to penicillin increases in the absence of CpsA and Psr.
GBS strains were grown in THY medium, normalized to OD600: 0.01 in PBS and treated with
3μg/mL Penicillin for 24 hours. (A) Treated (Red) and untreated (Blue) samples were then serially
diluted and plated on THY plates and counted. Statistical analysis represents significance between
untreated and treated cells for each strain. (B) Log CFU killed was calculated for each sample taking
Log10 (untreated/treated). Significance was determined by comparing log CFU killed of each strain
to that of wild-type GBS. Values represented are averages of 4 biological replicates. * P < 0.05, ** P
< 0.005.
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2.4.8 Absence of CpsA and Psr result in decreased capsule levels on the cell
Previous research confirms that the LCP family protein, CpsA, plays a role in the
amount of capsule on the cell as well as binding specifically to the capsule promoter
[92] and in the attachment of the capsular polysaccharide to the peptidoglycan cell wall
[96, 97, 99]. To determine if the LCP protein, Psr, also has an effect on the amount of
capsule on the cell, percoll density gradient centrifugation was performed as reported in
previous research with GBS CpsA [92, 105]. Buoyant density centrifugation sediments
cells based on their buoyancy. For examination of capsule level, the more capsule
produced, the less dense or more buoyant the cells. However, cells with less capsule
will result in higher density or less buoyancy. Results confirmed that capsule levels
decreased in the absence of CpsA as shown previously, but also in the absence of Psr,
and the ΔCpsA-ΔPsr double mutant (Figure 2-10A). Of note, a greater reduction of
capsule level was observed in the ΔPsr mutant strain than in that of the ΔCpsA mutant
strain. However, the double mutant ΔCpsA-ΔPsr strain and the ΔPsr strain both showed
a significant capsule reduction in comparison to the wild-type strain (Figure 2-10A).
To determine whether the capsule reduction is due to a reduction in overall
capsule production or due to capsule being released into the supernatant, dot blot
analysis was performed on supernatants of the four GBS strains. The dot blot results
showed capsule being released into the supernatant in the ΔCpsA and the ΔCpsA-ΔPsr
double mutant strains, but not in the case of wild-type and ΔPsr strains (Figure 2-10B),
confirming that CpsA functions as a ligase that attaches capsule onto the cell wall.
Buoyant density does not depend on chain length, as experiments using sonicated
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cultures to reduce all chains to the same length did not demonstrate a significant
change in the density (Figure 2-9).
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Figure 2-10 Capsule on the cell surface is decreased in the absence of LCP proteins
(A) Percoll Buoyant density centrifugation revealed less capsule in ΔCpsA, ΔPsr, and ΔCpsA-ΔPsr
strains in comparison to WT GBS. (B) Dot-Blot analysis on supernatants of WT, ΔCpsA, ΔPsr, and
ΔCpsA-ΔPsr strains reveals that more supernatant is released into the supernatant of ΔCpsA and
ΔCpsA-ΔPsr strains. Significance was determined by comparing densities of each strain to that of
wild-type GBS. Values represented are averages of 3 biological replicates. * P < 0.05

2.4.9

ELISA
In order to confirm the effects of the CpsA and the Psr proteins on capsule

amounts shown by buoyant density (Figure 2-9), a series of Enzyme-Linked
Immunosorbent Assays (ELISA) were performed, which directly quantifies the amount
of capsule by using an a-GBS capsule serotype Ia primary antibody. As expected, the
ΔCpsA strain capsule levels were lower than that of wild-type strain (Figure 2-11).
Surprisingly, this assay indicated significantly higher capsule measurements in the ΔPsr
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and the ΔCpsA-ΔPsr mutant strains in comparison to the wild-type strain, which is
directly opposing the results of buoyant density assay. This assay was performed using
two different substrates, Alkaline phosphatase and Horseradish peroxidase, producing
similar results (Appendix E).

GBS Capsule Measured via ELISA
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Figure 2-11 Capsule on the cells increase in the absence of Psr.
Capsule levels on cell surface were measured using an a-GBS capsule type Ia primary antibody and
a goat, pAB anti-Rabbit IgG conjugated to AP secondary antibody. Calculation of Alkaline
phosphatase substrate units revealed significantly less capsule on the cells of the ΔCpsA strain, and
significantly more capsule detected on the cells of the ΔPsr and the ΔCpsA-ΔPsr mutant strains.
Values represented are averages of 6 biological replicates. * P < 0.05

2.4.10 Absence of CpsA and Psr results in a decrease in GBS virulence in vivo
Previous studies have suggested that LCP proteins are important in virulence of
Gram-positive bacteria [92, 102, 105]. In order to determine whether the absence of the
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Psr protein results in increased recognition by the host immune system and
subsequently decreased virulence, the zebrafish infectious disease model was used to
determine virulence of the four GBS strains. Zebrafish larvae were injected into the yolk
sac at three days post fertilization with 100 CFU of each GBS strain and monitored over
72 hours. Results confirmed virulence of the wild-type GBS strain as the zebrafish
injected with this strain had 0% percent survival by 72 hours. All 3 mutant GBS strains
demonstrated various levels of attenuation with 13% survival in the ΔCpsA injected
group, 8% survival in the ΔPsr injected group and 32% survival in the ΔCpsA-ΔPsr
double mutant injected zebrafish (Figure 2-12).
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Figure 2-12 CpsA-Psr double mutant results in decreased virulence on GBS in vivo
GBS virulence was examined in vivo by injecting the yolk sacs of zebrafish 3 days post fertilization
with 100 CFU of WT, ΔCpsA, ΔPsr, and ΔCpsA-ΔPsr mutant strains. Values represented are
averages of 4 biological replicates, with a minimum of 105 total zebrafish injected per strain. *
P<0.05 *** P<0.0005
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2.5

Discussion
The capsular polysaccharide and peptidoglycan cell wall help to protect the

bacterial cell from multiple environmental factors that it may encounter within the host,
as well as serving as a shield against the host immune system. LCP family proteins
have been found to be crucial to the proper formation and assembly of the cell wall and
capsule in several bacterial species [92, 96, 102, 111, 112]. Consistent with previous
findings, GBS LCP family proteins examined in this study play an important role in the
synthesis and maintenance of the cell wall and cell wall associated capsule.
The slow growth rate of the ΔPsr and ΔCpsA-ΔPsr mutant strains of GBS in
comparison to the wild-type strain indicate that the Psr protein is an important
housekeeping protein that is required for proper growth of the GBS cell. The results
from the cell viability assay (live/dead assay) indicate that the slow growth rate of ΔPsr
and ΔCpsA-ΔPsr mutant strains is not due to increased cell death in these strains
during the early time frame of the growth curve (~3 – 5 hours), as cell viability is
negligibly affected during the same time period as shown by the live/dead assay during
log phase of growth. However, after reaching stationary phase and growing overnight
(~16 hours) the ΔCpsA-ΔPsr double mutant strain exhibited 41% cell death. This
suggests that Psr is required for both cell growth and cell viability over time. Moreover,
morphological changes such as longer chain lengths and larger, swollen cocci observed
in the cells of ΔPsr and ΔCpsA-ΔPsr strains supports the hypothesis that Psr plays an
important role in cell wall synthesis, and in the absence of it, the cell cannot maintain
proper shape. Inconsistent cell shape was also observed in LCP deficient strains of
Staphylococcus aureus [97] and Streptococcus mutans [107, 111-113], along with
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effects on cell division. TEM analysis on the ΔPsr and ΔCpsA-ΔPsr mutant strains will
need to be done to confirm cell division defects due to these mutations in GBS.
LCP protein deficiencies have also been linked to increased autolysis in bacteria.
For instance, in S. mutans, Psr and BrpA deficient strains demonstrated increased
autolysis after exposure to Triton X-100 [107]. Similarly in Staphylococcus aureus, LCP
mutants demonstrated greater susceptibility to autolysis after being treated with Triton
X-100 [102]. In this study, we examined the effect of sub-inhibitory concentrations of
Triton X-100 and lysozyme on the mutant strains and observed increased autolysis in
GBS when the Psr deficient strains were exposed to these reagents. These results are
supported by previous findings that linked LCP and related proteins to autolysis in S.
aureus [100, 102], S. pneumoniae [118] and S. mutans [107]. Since lysozyme affects
the linkage between NAM and NAG in the peptidoglycan cell wall [119] where LCP
proteins also function, our results suggest that in the absence of Psr, other LCP family
proteins, such as CpsA, can partially compensate for that function, as demonstrated by
the double mutant being the most sensitive strain to lysozyme.
b-lactam antibiotics such as penicillin are the first line of treatment used to treat
pregnant women during delivery that are known to be colonized with GBS [20]. Penicillin
works by inhibiting the binding of transpeptidases such as Penicillin binding proteins
and LCP proteins that fuse cell wall peptidoglycan chains to one another. The penicillin
susceptibility assay conducted in this study shows that in the absence of one LCP
protein, GBS becomes more susceptible to penicillin, suggesting that CpsA and Psr
proteins both play a role in protecting the cell from penicillin. The significant increase in
penicillin susceptibility in the ΔCpsA-ΔPsr double mutant strain suggests that LCP
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proteins have the ability to partially compensate for the functions of other LCP proteins
when they are missing. Similar antibiotic susceptibility assays have been performed in
S. aureus, where the deletion of the LcpC protein resulted in increases in susceptibility
to b-lactam antibiotics including penicillin [117].
We previously demonstrated that loss of the CpsA protein in GBS leads to
decreased capsule levels [92] similar to that shown for a Cps2A deletion of S.
pneumoniae [104]. While the results from the ELISA experiments confirm lower capsule
amounts in the DCpsA mutant strain, capsule amounts for the ΔPsr and the ΔCpsAΔPsr strains appear to be significantly higher than that of the wild-type strain. These
results are in direct opposition of the buoyant density centrifugation experiments, which
revealed that the ΔPsr and ΔCpsA-ΔPsr mutant strains have increased density
compared to the wild-type strain suggesting that loss of the Psr protein also leads to
decreased capsule on the cell surface of GBS. The contradiction between the results
obtained from these two methods may be due to the fact that the buoyant density
centrifugation method does not specifically measure capsule amounts, but rather the
density of the cells based on their components. In S. aureus the deletion of LCP
proteins results in the release of cell wall glycopolymers into the supernatant instead of
being attached onto the cell wall [99]; supporting the working model for the role of LCP
family proteins such as Psr, is that they are involved in the attachment of cell wall
glycopolymers onto the cell. It is therefore possible that the absence of the Psr protein
in GBS leads to decreased attachment of cell wall glycopolymers, leading to changes in
cell density. In order to determine whether the absence of the Psr protein results in
increased capsule production, Real-Time Quantitative Reverse Transcription PCR
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(qRT-PCR) must be performed to determine the possible effect of a psr deletion on the
expression of the capsule operon gene loci. A broader examination of proteomics can
also be done using Mass Spectrometry. Of note is the presence of excess capsule in
the supernatant of the ΔCpsA mutant strain as well as the ΔCpsA-ΔPsr double mutant
strain. This is expected as CpsA has been shown to be the ligase that attaches the
polysaccharide capsule to the cell wall [18, 23]. However, what was not expected was
what appears to be the absence of excess capsule in the supernatant (although not
quantitative) from the DPsr mutant strain, even though the buoyant density assay shows
less capsule on the cell surface in this mutant strain. Loss of buoyancy was not due to
the extra-long chains of cocci, as sonicated cultures yielded similar buoyancy levels to
untreated cultures that exhibited longer chain lengths and cell aggregation (Figure 2-7).
In vivo virulence assay results demonstrate that in the absence of either of the
CpsA or Psr proteins, GBS virulence decreases significantly, but the most significant
attenuation is observed in zebrafish that have been injected with the ΔCpsA-ΔPsr
double mutant strain. Studies involving BrpA deficient GBS also indicate decreased
attenuation in the mouse model of infection as well as in human whole blood [72].
Additionally, in vivo studies in S. aureus indicate that mice infected with a LcpC deficient
strain have a higher survival rate in comparison to those infected with the wild-type
strain [117]. In this study, the increased survival observed with the zebrafish infected the
LCP mutants may be due to several factors. Since the strains that are missing the Psr
protein, especially the ΔCpsA-ΔPsr double mutant strain, do not survive well in culture
over time, it can be speculated that these mutants also have decreased viability
overtime in vivo, and do not survive as long at the wild-type strain. Another explanation
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may be that the decreased cell wall integrity observed in the ΔPsr and the ΔCpsA -ΔPsr
mutant strains make them more susceptible to host defense systems used to eliminate
invading pathogens.
One consistency observed throughout this study was that the ΔCpsA-ΔPsr
double mutant strain showed a greater deficiency compared to the other 3 strains
analyzed including overall growth rate, sensitivity to autolysis, viability over time and
virulence in vivo suggesting that similar to other Gram-positive bacteria, LCP proteins
have partial redundancy in function. Previous studies in S. aureus, S. mutans, and S.
pneumoniae also show that in the absence of one LCP protein, other family members
often compensate for the missing protein, however double mutants are either non-viable
or significantly more susceptible to the assays compared to the wild-type or single LCP
mutant.
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3

THE EFFECTS OF THE ACCESSORY DOMAIN ON GBS CELL WALL AND
CAPSULE LEVELS

3.1

Chapter summary
As a vital streptococcal virulence factor, the capsular polysaccharide has been

extensively studied in many species, including Streptococcus agalactiae (GBS). Due to
its high conservation among many streptococcal species and its important role in the
capsule biosynthesis, the CpsA protein is of special interest. The accessory domain of
the CpsA protein is structurally similar to multiple proteins including a DNA Polymerase
Processivity Factor (DNA-PPF), the binding protein component of the ABC
Phosphonate Transporter and the Periplasmic Binding Protein Superfamily. These
structural similarities to binding proteins suggest that this domain may bind newly
synthesized polysaccharides and transfer it to the LytR domain of the CpsA protein,
which ultimately ligates the polysaccharide onto the cell wall. The experiments
described in this chapter aim to shed more light on the role of the accessory domain
and the interdomain region between the accessory and LytR domains on cell wall and
capsule production. The results presented suggest that while the absence of the
accessory domain and the interdomain region cause the formation of longer cocci
chains, it may not have a significant effect on capsule production in GBS.

3.2

Introduction
Streptococcus agalactiae (Group B strep, GBS) is an opportunistic pathogen that

is asymptomatically present in the gastrointestinal and reproductive tract of 25-35% of
individuals, but can cause invasive infection in neonates, immunocompromised adults,
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and the elderly with certain underlying health conditions [7-9]. Due to the shortcomings
of current antibiotic treatments, a better understanding of GBS virulence factors is
required so that new therapeutic targets can be determined. The capsular
polysaccharide is one of the most important virulence factors produced by GBS and is
synthesized by proteins encoded by the cps operon genes. cpsA is the first gene of the
cps operon and has been shown to regulate capsule production and aid in its assembly
by ligating capsular polysaccharide chains onto the bacterial cell wall [92, 104, 105].
The CpsA protein is 435 amino acids long, and consists of a short cytoplasmic N
terminal region, three transmembrane loops, and a long extracellular C-terminus,
consisting of two independently folding domains: the accessory domain and the LytR
domain (Figure 3-1).

extracellular

accessory domain

LytR domain

C

N
cytoplasm
Figure 3-1 CpsA protein topology
CpsA is a transmembrane protein consisting of a short N-terminus cytoplasmic region, 3
transmembrane domains the first of which contains a putative leucine zipper motif, and a long
extracellular region consisting of the accessory domain and the LytR domain separated by an interdomain region of approximately 21 amino acids long.

Previous research has determined that the cytoplasmic regions of the CpsA
protein bind to both promoter regions of the cps operon and regulate capsule production
61

[92], and the extracellular LytR domain ligates newly formed capsule chains onto the
cell wall[104]. Extensive studies have been performed to pinpoint the role of each
extracellular domain in capsule production in GBS. In these experiments several
truncations of the CpsA extracellular domains were constructed and subsequently
overexpressed from plasmids in the wild-type GBS and DCpsA GBS strains, and
capsule levels were measured via buoyant density centrifugation. The results from
these experiments indicated that when the LytR domain of the CpsA protein is absent,
capsule levels decrease (Figure 3-2). This occurs even in the wild-type GBS strain in
which a full length cpsA is expressed from the chromosome, indicating a dominant
negative effect of the accessory domain on capsule production. Analysis of the effect of
other truncated constructs on capsule levels pinpointed the dominant negative effect is
due to the 22 amino acid-long region between the accessory and LytR domains of
CpsA[105].

62

Figure 3-2 The CpsA protein interdomain region is important for capsule production
Overexpression of various cpsA gene constructs in wild-type GBS (black bars) and DCpsA GBS
(Gray bars) indicates different amounts of capsule production. Comparison of capsule levels in the
cpsA construct missing the LytR domain but having the accessory domain and the interdomain
region intact (cpsA-245) and the construct missing both LytR domain and the interdomain region
(cpsA-210) indicates that the interdomain region may be important in capsule production [105]

Further analysis of this interdomain region indicated that the addition of a
synthetic peptide corresponding to the interdomain region into GBS cultures, also
resulted in decreased capsule levels confirming that the region has an inhibitory effect
on the function of the CpsA protein in attaching the capsular polysaccharides onto the
cell wall (Figure 3-3) [105]. In addition, these results demonstrated that this inhibitory
effect can occur from the outside of the cell.
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Figure 3-3 Addition of a synthetic peptide to culture influences capsule production
Addition of a synthetic peptide corresponding to the interdomain region between the accessory
domain and the LytR domain of the CpsA protein to the growth medium containing the wild-type
GBS strain causes a reduction of capsule on the cells in comparison to the wild-type GBS strain
grown without peptide. Addition of a scrambled peptide to the culture medium as a negative control
does not influence capsule production [105]

To better understand the role of the accessory domain in CpsA protein function
two cpsA gene variants with specific deletions in the region encoding the accessory
domain were constructed. One construct (DAcc+) has a deletion of the region encoding
the accessory domain while leaving the cytoplasmic, the transmembrane, the
interdomain region and the LytR domain intact (Figure 3-4A). The second construct
(DAcc-) also has a deletion of the region encoding the accessory domain and, in
addition, the interdomain region, leaving the cytoplasmic, the transmembrane, and the
LytR domain intact (Figure 3-4B). The constructs were overexpressed in the wild-type
and DCpsA GBS strains in order to determine the role of the accessory domain on
growth rate, chain length, and capsule levels.
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3.3

Materials and Methods

3.3.1 Plasmid constructs
S. agalactiae (515) genomic DNA was used as a template to amplify the cpsA
gene region. A high-fidelity DNA polymerase, Q5 (New England Biolabs), was used and
the primers were specific to each reaction (Table 1). The Splice-Overlap-Extension PCR
(SOEing) technique was used to create the cpsA variant genes. Briefly, the short
fragment (Reaction 1, Figure 3-4)) used primers 5’ GBS-CpsA-RBS-BamHI and 3’ GBSCpsA-∆AD. The long fragment (Reaction 2 Figure 3-4) used primers 3’ GBS-CpsA-fullPstI and 5’ GBS-CpsA-∆AD. Both reactions were separated on 0.8% agarose gel to
confirm fragments sizes. Both reactions were gel purified using the GeneJet Gel
Extraction Kit (Thermo Fisher). The two PCR fragments had a ~30 bp overlap of the
same sequence added to the 3’ end of fragment 1 and the 5’ end of fragment 2 to
facilitate the joining of the 2 PCR fragments in the third reaction.
In the third reaction, the two PCR fragments were used as a template to SOE
(splice overlap extension) the fragments together, forming a full-sized fragment. Q5
DNA Polymerase (New England Biolabs) and the proper primers as depicted in table 1
were used to create this fragment. The reaction was separated on a 0.8% agarose gel
to confirm the final full-sized fragment. The full-sized fragment was gel purified using the
GeneJet Gel Extraction Kit (ThermoFisher), followed by digestion with BamHI and PstI.
The digested PCR SOEing fragment was ligated to the pLZ12-RofA-Pro vector, which
was also digested with BamHI and PstI restriction endonucleases. Constructs were
transformed into E. coli, positive colonies were selected via PCR and the sequence was
verified. Constructs were then transformed into the wild-type and ∆CpsA GBS strains.
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Table 1
Reaction
DAcc+ Reaction 1
DAcc+ Reaction 2
DAcc+ Reaction 3

DAcc- Reaction 1

Primer name

Primer sequence

5-GBS CpsA-RBS-BamHI

CGCGGATCCGTATTGGAGAATTACAATGTCTAATC

3’ D AD +IG region

GCTACCATAAGCATTATTAATGGTTGACTTAAATCC

3’ GBS-CpsA-Full-PstI

AAAACTGCAGTTATTCCTCCATTGTGTTC

5’ D AD +IG region

GGATTTAAGTCAACCATTAATAATGCTTATGTTAGC

5-GBS CpsA-RBS-BamHI

CGCGGATCCGTATTGGAGAATTACAATGTCTAATC

3’ GBS-CpsA-Full-PstI

AAAACTGCAGTTATTCCTCCATTGTGTTC

5-GBS CpsA-RBS-BamHI

CGCGGATCCGTATTGGAGAATTACAATGTCTAATC

3’ Delta Acc Dom

CATAATAATATTTACATCAGATCTAATGGTTGACTT
AAATCC

DAcc- Reaction 2

3’ GBS-CpsA-Full-PstI

AAAACTGCAGTTATTCCTCCATTGTGTTC

5’ Delta Acc Dom

GGATTTAAGTCAACCATTAGATCTGATGTAAATATT
ATTATG

DAcc- Reaction 3

5-GBS CpsA-RBS-BamHI

CGCGGATCCGTATTGGAGAATTACAATGTCTAATC

3’ GBS-CpsA-Full-PstI

AAAACTGCAGTTATTCCTCCATTGTGTTC
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LytR domain
RXN 1 ~300 bp

RXN 2 ~900 bp

Transmembrane domains
LytR domain
Interdomain region

RXN 3 ~1200 bp

B
Transmembrane domains

Interdomain region

Accessory domain

LytR domain

Transmembrane domains
LytR domain
RXN 2 ~720 bp

RXN 1 ~300 bp
Transmembrane domains
LytR domain
RXN 3 ~1020 bp

Figure 3-4 Construction of cpsA mutants via Splice Overlap Extension PCR
Construction of cpsA mutant missing the accessory domain was done by the creation of two PCR
fragments encoding the cytoplasmic and transmembrane domains of the CpsA protein, and one
fragment encoding the C terminal LytR domain. Two fragments were then fused via a third PCR
reaction. (A) depicts the construction of DAcc+ and (B) depicts the construction of DAcc-.
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3.3.2 Growth curve
Overnight cultures were subcultured 1:100 into 20ml of fresh THY medium and
grown statically at 37°C. Growth of cultures were monitored by measuring and recording
the OD600 once every hour for 6 hours using a spectrophotometer (Beckman Coulter,
PU530). Values represented are averages of 3 biological replicates.
3.3.3 Chain length analysis
Overnight cultures were pipetted onto a microscope slide with a coverslip and
observed using a Zeiss Axioscope 40 bright field microscopy at 1000X magnification
and imaged with Axiovision 4.7. Chain lengths were quantified using 10 fields of view
per sample. A minimum of 500 cocci per strain were quantified.
3.3.4 Capsule measurement by ELISA
Secondary antibody was pre-cleared as follows: 2.5mL of WT and DCpsA
overnight cultures were centrifuged, resuspended in 1mL Tris-buffered saline (TBS) and
treated with 1:100 final concentration of goat-anti-rabbit IgG-Alkaline Phosphatase
(Invitrogen,65-6122) at 4°C for 1 hour on rotator. Cells were then concentrated by
centrifugation and the supernatant was filtered using a 0.22µm (Sterlitech) syringe filter
and kept at 4°C until use.
Overnight cultures were normalized to 0.75 OD600, washed and resuspended in
TBST (Tris-buffered saline + 0.1% Tween 20) and treated with 1:10,000 final
concentration of primary antibody (Rabbit a-serotype 1a GBS) at 4°C for 1 hour on a
rotator. Cells were washed 3X with TBST and resuspended in 1mL TBST and
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supplemented with 20µL pre-cleared secondary antibody for a final concentration of
1:5,000 at 4°C for 1 hour on a rotator. Cells were washed 3X with TBS and
resuspended in 1mL TBS. Cells (50µL) were aliquoted in triplicate in a 96 well clear,
flat-bottom plate at the following dilutions, undiluted, 1:2 dilution and 1:4 dilutions, along
with cells treated only with 2° antibody as a control. Cells were supplemented with 150
µL pnpp buffer + phosphatase substrate tablets (Sigma, S0942). The plate was sealed
and incubated at room temperature for 1 hour in the dark. Assay results were measured
spectrophotometrically (OD405 and OD600) via plate reader (BioTek, Synergy 2) and AP
(alkaline phosphatase) unites were calculated using the following formula:
!"#$%
('() + , + !"-$$)

𝑥 1000 = 𝐴𝑃 𝑢𝑛𝑖𝑡𝑠

3.3.5 Capsule measurement by Buoyant density
Buoyant density was determined using linear Percoll (GE Healthcare) gradients
as described previously [116]. Briefly, 4mL Percoll, supplemented with 0.15M NaCl,
diluted to low (1.085 g/cm3) density was carefully overlaid onto 4mL Percoll diluted to
high (1.120 g/cm3) density in a 10mL tube and placed at a 15° angle overnight to allow
formation of a continuous linear gradient. Next day, gradients were gently placed
vertically and allowed to settle at least 30 minutes prior to centrifugation. Overnight
bacterial cultures were normalized to an OD600 = 0.6 in 1ml and concentrated to a
volume of 100μL in phosphate buffered saline. (PBS) The prepared cultures were
carefully added to top of the gradient and gradients were centrifuged 30 min at room
temperature at 5,000 rpm in a swinging bucket (Eppendorf Centrifuge 5403 with Rotor
16A4-44). Distance traveled in the gradient was measured from the bottom of the
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meniscus to the center of the cell band, and density was determined by calculation of a
linear curve from distance traveled by beads of known density (GE Healthcare). Values
represented are averages of 3 biological replicates.

3.4

Results

3.4.1 Absence of the accessory domain does not cause a difference in GBS
growth rate
To determine whether the absence of the accessory domain would influence the
GBS growth rate, wild-type GBS and ∆CpsA GBS strains containing cpsA mutant
constructs missing only the accessory domain (∆Acc+) and another construct missing
the accessory domain and the interdomain region (∆Acc-) were grown in liquid THY and
their growth rate was determined via OD600 measurements (Figure 3-5). Although the
wild-type GBS strain containing the empty vector control grew at a slightly slower rate
than all other strains, this difference was not deemed significant.
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Figure 3-5 GBS growth rate is not affected by the absence of the accessory domain.
Overnight cultures were sub-cultured 1:100 in fresh media and grown statically at 37°C. OD600 was
measured via spectrophotometer. No notable difference in growth rate was observed between
strains. Graph is representative of 3 separate growth curves

3.4.2 Absence of the CpsA accessory domain results in increased cocci chain
length
To determine if the absence of the accessory domain would result in a change in
cocci chain length, 10 fields of view per strain were imaged via bright field microscopy
and quantified. As expected, the ∆CpsA strain containing an empty vector control
(∆CpsA-vector) produced longer chains with a mean value of 3.25 cocci per chain in
comparison to 1.78 cocci per chain for the wild-type strain containing an empty vector
control (WT-vector) (Figure 3-6). Overexpression of the two ∆Acc CpsA constructs in
the wild-type GBS strain did not produce a significant change in chain length in
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comparison to the WT-vector, as the mean value was 1.78, 1.86, and 1.88 cocci per
chain for the three strains: WT-vector, the wild-type GBS strain plus a plasmid
expressing CpsA with the accessory domain missing (WT-Acc+) and the wild-type GBS
strain plus a plasmid expressing CpsA with the accessory domain and the interdomain
regions missing (WT-Acc-) (Figure 3-6). Notably, when the two accessory domain
deletion constructs were overexpressed in ∆CpsA GBS, greater variation in chain length
was observed in comparison to the ∆CpsA-vector strain (Figure 3-2). Chain length
mean values for the ∆CpsA plus an empty vector (∆CpsA-vector) strain, the ∆CpsA
plus a plasmid expressing CpsA with the accessory domain missing and the
interdomain regions missing (∆CpsA-∆Acc-) strain, and the ∆CpsA plus a plasmid
expressing CpsA with the accessory domain missing (∆CpsA-∆Acc+) strain were 3.25,
4.06, and 6.35 cocci per chain respectively.
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Figure 3-6 Loss of the accessory domain affects GBS bacterial chain length
Overnight cultures were mounted on microscope slides and visualized via brightfield microscopy. (A)
Micrograph images of each of the 6 GBS strains pipetted onto a glass slide. (B) A quantitative
representation of the chain length analysis. Images using 10 fields of view from each strain were
used to quantify the number of cocci in each chain, with a green line indicative of median chain
length.
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Figure 3-6 Continued
B

Chain length

Chain Length Analysis of GBS Strains

3.4.3 Capsule production is not significantly affected by the absence of the CpsA
accessory domain
The amount of capsule produced by each strain was measured using both
Enzyme-linked immunosorbent assay (ELISA) and Buoyant density centrifugation
methods. Results from both methods show that the ∆CpsA-vector strain contains less
capsule than the WT-vector strain as expected, since CpsA plays a vital role in the
production of the capsule. Overexpression of the ∆Acc+ and ∆Acc- constructs in ∆CpsA
GBS did not result in a significant difference in the amount of capsule produced in
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comparison to the ∆CpsA-vector strain. Overexpression of the ∆Acc+ construct in the
wild-type GBS strain showed no significant difference in capsule production in both
experimental methods. The overexpression of the ∆Acc- and the ∆Acc+ constructs in
the wild-type GBS strain resulted in a slight reduction in capsule in the buoyant density
centrifugation, however this result was only observed in the wild-type-∆Acc- strain in the
ELISA analysis.

Capsule measurement vis ELISA
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0
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∆CpsA-Vector

WT-∆Acc+

∆CpsA-∆Acc+

WT-∆Acc-

∆CpsA-∆Acc-

Figure 3-7 The effect of the loss of the accessory domain on capsule levels measured via
ELISA
Capsule levels on cell surface were measured using an a-GBS capsule serotype Ia primary antibody
and a goat, polyclonal antibody anti-Rabbit IgG conjugated to AP secondary antibody. Calculation of
Alkaline phosphatase units revealed no significant difference in capsule on the cells of any of the
tested strains. Values represented are averages of 6 biological replicates.
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Figure 3-8 The effect of the loss of the accessory domain on capsule levels measured via
buoyant density centrifugation
The buoyancy of overnight cultures of wild-type and DCpsA GBS strains containing an empty vector
control, full length CpsA, the DAcc+ and the DAcc- constructs was measured via buoyant density
centrifugation and the density of each culture was subsequently calculated. Values represented are
averages of 2 biological replicates. No significant difference was observed between relevant strains.

3.5

Discussion
The CpsA protein has been extensively studied as a possible therapeutic target

by bacteriologists over the years, due to its vital role in capsule synthesis and assembly
and consequently on virulence. Despite extensive studies on the CpsA protein, the role
of the extracellular accessory domain has remained largely unknown. Consistent with
previous findings, this study confirms the effect of a deletion of the cpsA gene on the
cocci chain length and capsule production in GBS, as the cocci chain lengths increase,
and production of capsule decreases in the absence of the CpsA protein. In this study,
two variant cpsA gene constructs, one with a deletion of the accessory domain and one
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with a deletion of the accessory domain plus the interdomain region between the
accessory and LytR domains, were created and analyzed. Results from the analysis of
growth rates showed no significant differences between any of the mutant constructs in
comparison to wild-type and ∆CpsA GBS strains containing empty vector control
plasmid. These results were not surprising, as other studies performed in our lab have
not observed that loss of the CpsA protein affects growth rate in GBS. Our results
confirm that when a CpsA protein missing the accessory domain is expressed in GBS,
there is no significant influence on GBS growth rate.
Results from the analysis of cocci chain length indicate that overexpression of the
∆Acc+ and ∆Acc- constructs in the wild-type GBS strain causes a slight increase in
chain length in comparison to the wild-type strain with the empty vector control, but this
increase is not significant as the mean and median values are very similar between all
three strains. However, overexpression of the ∆Acc+ and ∆Acc- constructs in the ∆CpsA
GBS strain, resulted in a more distinct increase in chain length in comparison to the
∆CpsA strain containing the empty vector control plasmid. This increase was more
pronounced in the ∆CpsA-∆Acc+ strain where the accessory domain has been deleted
but the interdomain region is intact. This may be due to a direct effect of the interdomain
region on chain length, as observed previously, where data indicated that the
interdomain region has a dominant negative effect on capsule production in GBS [105].
Taken together, the cocci chain length analysis data indicates that the accessory
domain alone does not affect chain length, but that the overexpression of the
interdomain region affects the cell wall, leading to an increase in chain lengths.
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The results from the measurement of capsule production by ELISA and Buoyant
density assays, indicate that overexpression of the ∆Acc+ and ∆Acc- constructs in the
∆CpsA GBS strain does not result in any significant change in capsule production in
comparison to the ∆CpsA strain containing the empty vector control plasmid. Of note,
the results from the ELISA indicate that when ∆Acc- construct is overexpressed in the
wild-type GBS strain, less capsule is produced compared to when the ∆Acc+ construct
overexpressed in the wild-type GBS and the wild-type strain containing the empty vector
control plasmid. One possible explanation for the decreased capsule levels in the
absence of the accessory domain and the interdomain region may be that the LytR
domain is fused directly next to the third transmembrane domain of the CpsA protein,
and therefore may not have the required flexibility needed to functionally ligate the
newly formed capsular polysaccharides onto the cell wall, resulting in the release of the
polysaccharides into the culture supernatant and subsequently, decreased detection of
capsule amount on the cell surface. However, the results from the buoyant density
centrifugation assay did not confirm these results, as it showed the same amount of
capsule for all three wild-type strains. The difference in the results from the two assays
may be due to either the sensitivity levels of the ELISA compared to the buoyant density
assay or the methodology of the assays themselves.
To examine how the structural domains of the CpsA protein compare to other
known proteins found in protein databases, the HHpred bioinformatics toolkit was used
to align, the CpsA protein sequence with similar proteins. As expected, the LytR domain
of the CpsA protein aligned with other LCP family proteins. The Accessory domain
aligned with a DNA Polymerase Processivity Factor (DNA-PPF), as well as with the
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Binding Protein Component of the ABC Phosphonate Transporter, and the Transferrin
Family of the Periplasmic Binding Protein Superfamily (BPB-2 transferrin). All of the
above-mentioned proteins act as binding or clamp proteins that bind to specific
substrates or cell components. The working theory for the attachment of capsular
polysaccharides to the cell wall is that newly formed polysaccharides are transferred
from the Wzy (CpsH) protein via a complex consisting of the CpsB, CpsC and CpsD
proteins, to the CpsA protein, which attaches the polysaccharide chain onto the cell wall
[91]. Based on this information, it is possible that the accessory domain of the CpsA
protein also acts as a binding protein that either binds the capsular polysaccharide and
transfers it to the LytR domain to be ligated onto the cell wall, or it may bind to CpsC
carrying the capsular polysaccharide in order to keep that protein stationary so that the
LytR domain of CpsA can grab the capsular polysaccharide and attach it to the cell wall.
Since the mutations that were made in the cpsA gene were so close to the
transmembrane domain, it is possible that the change in the structure of the protein
results in the protein not being properly localized to the membrane. In order to confirm
correct CpsA protein localization, fractionation experiments followed by western blots to
confirm cellular localization of CpsA will have to be performed. Additionally, in vivo
virulence assays will need to be done to examine the effects of the deletion of the
accessory domain and the interdomain region on GBS virulence.
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APPENDIX A
GBS SUSCEPTIBILITY TO VANCOMYCIN
Vancomycin is a glycopeptide antibiotic that is sometimes used to treat GBS
infections. Vancomycin works by binding to D_alanine-D-alanine residue of growing
peptidoglycan chains, and subsequently inhibiting cell wall synthesis. The assay was
performed by exposing the wild-type GBS strain, The ΔCpsA, The ΔPsr, and the
ΔCpsA-ΔPsr mutant strains to different concentrations of vancomycin as depicted in the
figure below for 24 hours and measuring at OD600. The results were highly variable,
however, the general trend clearly indicates that both the ΔCpsA and the ΔPsr mutants
lose their sensitivity to vancomycin in comparison to the wild-type GBS strain (Figure A1). The ΔCpsA-ΔPsr double mutant, however, is more susceptible to vancomycin
treatment. These results will need to be verified by plating cultures and determining their
growth on THY plates.
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GBS Susceptibility to Vancomycin
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Figure A-1 Vancomycin susceptibility decreases in CpsA and Psr single mutant
strains but increases in double mutant strain.
GBS strains were normalized to OD600: 0.01 and incubated with 1.5 µg/ml vancomycin for 24
hours at 37°. OD600 measurements reveal decreased susceptibility to vancomycin in the case
of the ΔCpsA and ΔPsr strains in comparison to that of the wild-type strain. The ΔCpsA-ΔPsr
double mutant demonstrated increased vancomycin susceptibility. Values represented are
averages of 9 biological replicates
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APPENDIX B
GBS SUSCEPTIBILITY TO STREPTOMYCIN
Streptomycin is an antibiotic that works by inhibiting the initiation of protein
synthesis. It achieves this by binding to the 29S protein and the 16S rRNA of the
bacteria’s 30S ribosomal subunit. Because streptomycin’s mechanism of action is not
related to the cell wall, it was used as a negative control in investigating the role of the
CpsA and the Psr proteins in antibiotic susceptibility of GBS. Comparison of OD600
values of treated and untreated cells indicate that streptomycin susceptibility increases
withe single deletions of either CpsA or Psr as depicted in figure B-1 below.
Surprisingly, the ΔCpsA-ΔPsr double mutant strain shows a substantial decrease in
sensitivity to streptomycin by showing double the growth and survival in comparison to
the wild-type strain. These results will need to be verified by plating cultures and
determining their growth on THY plates.
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GBS Susceptibility to Streptomycin
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Figure B-1 The ΔCpsA-ΔPsr double mutant stain shows reduced susceptibility to
streptomycin.
GBS strains were normalized to OD600: 0.01 and incubated with 250 µg/ml streptomycin for
24 hours at 37°. OD600 measurements reveal increased streptomycin susceptibility in the
DCpsA and DPsr mutants, and a substantial decrease in susceptibility in the ΔCpsA-ΔPsr
double mutant strain. Values represented are averages of 3 biological replicates
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APPENDIX C
GBS SUSCEPTIBILITY TO CHLORAMPHENICOL
Chloramphenicol is another antibiotic that inhibits protein synthesis. Its
mechanism of action is to bind the 50S ribosomal subunit and prevent new amino acid
residues to be added to peptide chains. This antibiotic was also used as a negative
control in the study to determine the role of LCP proteins on antibiotic susceptibility in
GBS, as discussed in chapter 2. These preliminary results indicate a similar level of
chloramphenicol sensitivity with a slight decrease in sensitivity in the ΔCpsA, the ΔPsr,
and the ΔCpsA-ΔPsr mutant strains in comparison to the wild-type strain (Figure C-1).
This experiment will need to be repeated in order to confirm these preliminary results.
Additionally, these results will need to be verified by plating cultures and determining
their growth on THY plates
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GBS Susceptibility to Chloramphenacol
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Figure C-1 Chloramphenicol sensitivity is not affected by the absence of CpsA and
Psr in GBS.
GBS strains were normalized to OD600: 0.01 and incubated with 4 µg/ml chloramphenicol for
24 hours at 37°. OD600 measurements reveal no significant change in chloramphenicol
sensitivity between the mutant strains and wild-type GBS. Values represented are averages
of 2 biological replicates.
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APPENDIX D
GBS SUSCEPTIBILITY TO PENICILLIN
As the main antibiotic used to treat GBS infection, GBS susceptibility to penicillin
was examined in wild-type GBS and DCpsA strain, the DPsr strain and the DCpsA-DPsr
double mutant strains. The result from this experiment indicates that in the absence of
Psr and CpsA-Psr, penicillin susceptibility increases, whereas the DCpsA strain seems
to become less sensitive to penicillin. This result was not corroborated when penicillin
exposed strains were plated, as the DCpsA strain showed similar penicillin sensitivity in
comparison to the DPsr mutant strain (Figure 2-8).

GBS Susceptibility to Penicillin
1.20
1.00
0.80
0.60
0.40
0.20
0.00
WT 515
No Antibiotic

515 ∆CpsA
0.01 μg/ml

515 ∆Psr
0.03 μg/ml

0.06 μg/ml

∆CpsA ∆Psr
0.12 μg/ml

Figure D-1 Penicillin sensitivity is affected by the absence of CpsA and Psr in GBS.
GBS strains were normalized to OD600: 0.01 and incubated with 0.01, 0.03, 0.06, and 0.12
µg/ml chloramphenicol for 24 hours at 37°. OD600 measurements were read on plate reader
after 24 hours. Values represented are averages of 9 biological replicates
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APPENDIX E
GBS CAPSULE MEASUREMENT VIA ELISA USING HRP SUBSTRATE
Capsule measurement results via ELISA using alkaline phosphatase substrate
did not corroborate our results from the buoyant density centrifugation assay (see
chapter 2). In order to rule out a possible involvement of the substrate, the ELISA
experiment was repeated using a horseradish peroxidase substrate. The results from
this assay, indicate reduced capsule on the cells of the DCpsA GBS strain but no
significant difference in capsule measurement between the wild-type strain, the DPsr
strain and the DCpsA-DPsr double mutant strain. This is slightly different from the ELISA
(AP) assay (Figure 2-10), which indicated increased capsule on the cells of the DPsr
strain and the DCpsA-DPsr double mutant.
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GBS Capsule measurement ELISA (HRP Substrate)
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Figure E-1 Capsule on the cells increase in the absence of Psr.
Capsule amounts on the cell surface were measured using an a-GBS capsule type Ia
primary antibody and a goat, pAB anti-Rabbit IgG conjugated to HRP secondary antibody.
Calculation of HRP substrate units revealed slightly less capsule oncells of the ΔCpsA strain,
but no significant difference in capsule detected on the cells of the ΔPsr and the ΔCpsA-ΔPsr
mutant strains.
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APPENDIX F
THE LEUCINE ZIPPER MOTIF OF THE CPSA PROTEIN
F.1

Introduction
Leucine zipper motifs are common protein-protein interaction domains that can

contribute to both homodimerization and heterodimerization in proteins, and are
commonly characterized by 5-6 leucine residues which are 6 amino acids apart [120].
In the CpsA protein, a leucine zipper motif was discovered in the first transmembrane
domain which may be involved in the interaction of the CpsA protein with itself or with
other proteins within GBS that may be involved in cell wall or capsule biosynthesis. The
preliminary data shown in this appendix aims to answer some of the questions about
the involvement of this leucine zipper motif in dimerization and capsule production.
F.2

Materials and Methods

F.2.1 Plasmid constructs
A construct of the cpsA gene was created with the leucine zipper motif mutated via
site directed mutagenesis, where three of the leucine residues were changed to alanine
residues (Figure F-2). Three separate PCR reactions were performed using a high
fidelity Q5 DNA polymerase (New England Biolabs), DNA isolated from wild-type GBS
as template and sets of primers as depicted in table 1, in order to create the leucine
zipper mutated construct of the cpsA gene. A FLAG tag was added to the N-terminal
end of this construct via PCR and then it was inserted into the pUC19 expression vector
with a LacZa promoter and ampicillin resistance. The full length wild-type cpsA
construct was fused with an N-terminal MBP tag and inserted into a pLZ12-RofA-Pro
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expression plasmid with a RofA promoter and chloramphenicol resistance. Pairs of
constructs were then co-transformed into TOP-10 E.coli cells as depicted in figure F-1.
F.2.2 Co-immunoprecipitation
Overnight cultures were subcultured into 40 mL LB broth with appropriate
antibiotics, and grown to OD600 = 0.5. The cells were then washed with PBS and
treated with 1% formaldehyde in order to crosslink proteins for 10 minutes at 30°C. The
cells were quenched by 0.125M final concentration of Glycine for 5 minutes at room
temperature to stop the crosslinking. Cells were subsequently lysed via treatment with
lysozyme buffer for 2 hours at 37°C, followed by treatment with lysis buffer for an
additional 45 minutes at 37°C. The cells were centrifuged and the supernatant
containing a mixture of proteins was removed. Proteins of interest were then collected
(pulled down) using anti-MBP magnetic beads. Western blots were then performed.
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MBP

Wild-type cpsA

FLAG

Wild-type cpsA

FLAG

Leucine zipper mutant cpsA
experimental group

Positive control

MBP

Wild-type cpsA

Wild-type cpsA

E.coli

E.coli

MBP

FLAG

FLAG

Wild-type cpsA

Leucine zipper
mutant cpsA

Figure F-1 Construction of wild-type cpsA and leucine zipper mutated cpsA gene constructs.
Wild-type and leucine zipper mutated cpsA constructs were created and tagged with either MBP or
FLAG, as shown above. Pairs of constructs were then co-expressed in E.coli cells to be used in coimmunoprecipitation studies.

F.3

Results and discussion
The leucine zipper mutated construct of the cpsA gene was created via site

directed mutagenesis, where three of the leucine residues were changed to alanine
residues in order to effectively dismantle the leucine zipper motif in the first
transmembrane domain of the CpsA protein and its dimerization properties.
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1st Transmembrane domain sequence variation between wildtype and mutant CpsA
Wild-type GBS
L R V I N L F L L V I F I L L S V V S L F L M Y R H H F L A
Mutated GBS
L R V I N L F A L V I F I L A S V V S L F A M Y R H H F L A

Figure F-2 Mutations in the leucine zipper motif of the CpsA proteins
Three leucine residues within the identified leucine zipper motif on the first transmembrane domain
of the CpsA protein were changed to alanine residues via site-directed mutagenesis

Co-immunoprecipitation and subsequent western blots were performed in order
to determine whether the wild-type CpsA protein homodimerized with itself, and whether
the leucine zipper mutated CpsA protein loses its binding ability to the wild-type CpsA
protein. The membrane blotted with an anti-FLAG antibody showed that the FLAGtagged leucine zipper mutated CspA construct overexpressed in the wild-type GBS
strain as well as the FLAG-tagged wild-type CpsA construct overexpressed in the wildtype GBS strain were pulled down with the MBP magnetic beads. These results suggest
that the homodimerization of the CpsA protein may not be significantly affected by the
disruption of the leucine zipper motif. However, the FLAG tagged wild-type CpsA and
the FLAG tagged leucine zipper mutant, which were run without co-immunoprecipitation
as negative controls, also showed the same bands, while they were not supposed to be
pulled down by magnetic beads. Due to a high background, MBP-tagged CpsA was not
visible on the MBP blot. Further optimization is needed in order to properly visualize this
protein. One of the reasons for the high amount of background may be due to the
difference in copy number of the two expression vectors –pLZ12-RofA and pUC19-102

used to clone the cpsA constructs, as the pLZ12-RofA vector is a relatively low copy
number plasmid, but pUC19 is a high copy number plasmid. In order to alleviate this
problem, a co-expression vector –pCDF Duet-1- with the capacity to simultaneously
express two constructs from two promoters from a single plasmid was chosen. While
insertion of wild-type cpsA gene into this plasmid proved to be difficult, it was finally
achieved. This construct can now be used for co-immunoprecipitation along with the
leucine zipper mutant construct in the pLZ-12-RofA expression vector, as they possess
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Figure F-3 Co-immunoprecipitation of full length CpsA with leucine zipper mutated CpsA.

Lane 1: protein ladder, Lane 2: MBP-full length CpsA and FLAG-full length CpsA eluate, Lane 3:
MBP-full length CpsA and FLAG-full length CpsA unbound, Lane 4: MBP-full length CpsA and
FLAG-leucine zipper mutant eluate, Lane 5: MBP-full length CpsA and FLAG-leucine zipper mutant
unbound, Lane 6 & 7: MBP-full length CpsA (control), Lane 8 & 9: FLAG-full length CpsA (control),
Lane 10 & 11: FLAG-leucine zipper mutant. (A) membrane blotted with MBP specific primary
antibody and (B) membrane blotted with FLAG specific antibody.

103

The FLAG-tagged wild-type cpsA gene and the FLAG-tagged leucine zipper
mutant cpsA gene were separately overexpressed in the wild-type and DCpsA GBS
strains in order to examine the effect of the leucine zipper on capsule production in
GBS. As expected, the DCpsA GBS strain with the empty vector control revealed less
capsule on the cell surface in comparison to the wild-type GBS strain with the empty
vector control. When the FLAG-tagged wild-type CpsA protein was overexpressed in
the wild-type GBS strain, no significant change in capsule production was observed, but
when the leucine zipper mutant CpsA protein was overexpressed in the wild-type GBS
strain, capsule production showed a slight decrease in comparison to the wild-type GBS
strain with the empty vector control. The overexpression of the FLAG-tagged wild-type
CpsA protein in the DCpsA GBS strain resulted in complementation of capsule
production. The same level of complementation was observed when the FLAG-tagged
leucine zipper mutant construct was overexpressed in the DCpsA GBS strain. Taken
together, these results suggest that the leucine zipper does not have a significant effect
on capsule production in GBS. However, this experiment will need to be repeated
several times to ensure that preliminary results are reproducible.
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Figure F-4 The leucine zipper motif of CpsA is not directly involved in capsule production.
ELISA performed on wild-type and DCpsA GBS strains overexpressed with an empty vector control,
FLAG tagged full length cpsA, and FLAG tagged leucine zipper mutated cpsA was performed in
order to measure capsule levels on cell surface. The experiment was performed using an a-GBS
capsule type Ia primary antibody and a goat, pAB anti-Rabbit IgG conjugated to AP secondary
antibody.
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